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1. INTRODUCTION 
 
Malign neoplasms are currently treated by surgical resection, radiation- and 
chemotherapy. More than 60% of the drugs used against cancer in western 
medicine are derivatives of naturally occurring substances (metabolites of plant 
or microbial origin) (Cragg and Newman 2006). Many traditional healing plants 
successfully passed several hundred years of empirical testing against specific 
diseases and thereby demonstrating that they are well tolerated in humans. 
Although quite a few ethno-pharmacological plants are applied against a variety 
of conditions there are still numerous plants that have not been cross-tested in 
diseases apart from the traditional applications. 
 
The potential of plants of the tropical rain forest as a source for medicinally 
useful compounds is found in its high genetic diversity and its high 
concentration of active compounds. We have therefore focussed our interest on 
the knowledge of herbalists and curanderos/curanderas of very old cultures or 
civilizations living in high biodiversity regions still practising their traditional 
healing methods based on a rich botanical pharmacy. The long lasting 
medicinal experience of the Mayas of the tropical rain forest of Guatemala is a 
particularly precious knowledge, and moreover some Maya populations have 
been rather isolated for hundreds of years and still treat and heal diseases of 
many kinds using natural remedies from the neighbouring tropical rain forests, 
which are amongst the richest biodiversity areas in the world. Since the Maya 
medicine neither knew about leukaemia or cancer, nor remedies against it, our 
concept of plant selection was their traditional use (and they still are in use) 
against severe inflammations, because there are a variety of similar signalling 
pathways which are commonly up-regulated both in inflammatory conditions 
and in cancer. 
Therefore, the aim of this project is the isolation of new lead substances with 
anti-neoplastic activity spectrum from scientifically as yet unexplored plants. It is 
intended to progress in a similar way as for the development of Taxol, which 
was already known as medicinal remedy (as metabolite in the bark of several 
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Taxus species) to the indigenous North American tribe of the Quinault who 
treat(ed) stomach and kidney complications. Two principle parameters guided 
the conception of this project: 
1) the traditional use to treat inflammatory conditions and  
2) the absence of records in western medicinal- and patent databases. 
 
Here we describe for the first time the anti-cancer activity of extracts of two 
ethnopharmacological healing plants used against various inflammatory 
scenarios, Pluchea odorata (Asteracea) and Syngonium podophyllum (Araceae) 
in HL-60 promyeloic leukaemia cells and MCF-7 breast cancer cells. The plants 
selected as such were extracted with solvents of increasing polarity (petroleum 
ether, dichlormethan, ethyl acetate, methanol and water). The extracts were 
tested in human HL-60 promyelocytic leukaemia and MCF-7 breast cancer cells 
regarding their anti-cancerogenic properties. The best extract types of the most 
bioactive plant parts were specifically investigated regarding their apoptosis-
inducing potential. Western blot and FACS analyses aimed to obtain data on 
the underlying mechanisms. 
 
As a negative control L. sativa was extracted and tested the same way as P. 
odorata and S. podophyllum.  
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2. LITERATURE SURVEY 
 
2.1. Cell-cycle 
 
The development of cancer is associated with disorders in the regulation of the 
cell cycle. Complex networks of regulatory factors dictate whether cells 
proliferate or die (Meeran and Katiyar 2008). Cell external signals decide until 
cells commit to go through the entire cycle, and cell intrinsic information control 
the progression through the cell cycle. Both together determine whether cells 
enter a division cycle. The basic components of this machinery are conserved in 
all eukaryotes (Heuvel 2005). 
 
The DNA in every mammalian cell is under constant attack by agents that can 
either directly damage one of its three billion bases or break the phosphodiester 
backbone on which the bases reside, for example by solar radiation, polycyclic 
aromatic hydrocarbons and cigarette smoke, etc. Damage to cellular DNA can 
result in the development of cancer. Cells have developed several defense 
mechanisms to cope with this constant attack on their DNA, for example direct 
repair, halting cell-cycle progression or apoptosis (Meeran and Katiyar 2008). 
 
2.1.1. Overview of cell cycle progression 
The cell cycle is a recurring sequence of events that includes the duplication of 
cell contents and subsequent cell division. Traditionally the cell cycle in 
eukaryotic cell has been divided into four phases: 
 
Figure 1: Cell Cycle (Heuvel 2005) 
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(G1) Gap phase 1 ? connect the completion of M phase to initiation of  
  S phase in the next cycle 
(S) DNA synthesis ? accurate duplication of the genome 
(G2) Gap phase 2 ? cells prepares itself for division 
(M) Mitosis ? chromosomes were separated and the cell divides 
(Meeran and Katiyar 2008) 
 
Dependent on environmental and developmental signals, cells in G1 may 
temporarily or permanently leave the cell cycle and enter a quiescent or 
arrested phase know as G0 (Heuvel 2005). 
 
The process of mitosis is divided into five scenes: 
a) Prophase: incipient chromosomal condensation 
b) Metaphase: chromosomal alignment 
c) Anaphase: segregation of sister chromosome 
d) Telophase: enclosure of the new chromosome in  
  the new core 
e) Interphase: subsequent division of cellular material 
  leading to the next interphase 
 
Figure 2: Mitosis 
 
The Cell cycle is regulated by sequential activation and inactivation of many 
“check points”. They monitor the status of the cell as well as environmental 
cues. Check points are gene products or subset of gene products that, when 
mutated, confer independence on a cellular process that was previously 
dependent upon completion of another cellular process. In order to ensure 
proper cell cycle progression, the cells go through many internal checkpoints 
onto the next step (Meeran and Katiyar 2008). 
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Cyclins 
Cyclins are able to form a complex with a CDK partner and thereby control 
various phases of the cell cycle (illustrated at figure 1). Their expression pattern 
dictates the point in the cell cycle at which they act. There are two types of 
cyclins:  
• cell-cycle related cyclins (cyclin A, B, D and E) and  
• non-cell cycle related cyclins (cyclin H and C) 
Of the cell-cycle related cyclins, cyclin D and E play an important role in the 
transition from the G1 to S phase. Cyclin A has functions in both S phase and 
mitosis (Meeran and Katiyar 2008). 
 
Cyclin dependent kinases (CDK) 
Progression through the cell-division cycle is driven by activation and 
inactivation of cyclin-dependent kinases (CDKs). They trigger the transition to 
subsequent phases of cycle (Heuvel 2005). Different members of the CDK 
family, in association with different cyclins, switch throughout the cell cycle. 
Other family members regulate transcription, differentiation, and nutrient uptake, 
as well as other cellular functions. CDK protein levels are constant throughout 
the cell cycle; the CDKs are only functional during district intervals within the 
cell cycle. Notably, to enter the S phase all cells must activate cyclin-dependent 
kinases (Meeran and Katiyar 2008). 
 
CDK inhibitors (CDKI) 
There are two classes of Cdk inhibitors:  
• the INK4 inhibitors, with p16INK4A, P15INK4B, p19INK4D and p18INK4C,  
• and the Cip/Kip inhibitors, with p21Waf1/Cip1, p27Kip1 and p57Kip2. 
The INK4 family specifically inhibits the cell cycle, while the Cip/Kip family can 
inhibit Cdk activity during all phases of the cell cycle (Pietenpol and Stewart 
2002). The relative concentrations of each of the two families of inhibitors 
determine their distribution among the various cyclin/CDK complexes and finally 
affect G1 progression. Cip1/p21 inhibits DNA replication and arrests growth in 
G1. Kip1/p27 also plays a role in the regulation of the restriction point. The 
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members of the INK4 family specifically block G1 progression by inhibiting the 
association of CDK4/6 with cyclin D. Impairment of a growth-stimulatory 
signaling pathway has been shown to stimulate the expression of CDKIs 
(Meeran and Katiyar 2008). 
 
2.1.2. Cell-cycle control: checkpoints 
Cells are constantly subject to mutation of their DNA, which is detrimental to the 
cells. But only rarely of that cells flourish as pathologic tumours. Cells respond 
to DNA damage by halting cell cycle progression or apoptosis. Failure of the 
quality control check points or a loss of balance of the regulatory molecules 
plays a major role in the development of cancer (Meeran and Katiyar 2008).  
 
The choice of which repair system to use depends both on the type of lesion 
and on the cell-cycle phase of the cell. For example, a DNA double-strand 
break in S and G2 phases is readily repaired by homologous recombination 
fusion to it´s intact sister chromatid. However, as cells progress into G2/M, the 
chromosomes are condensed in a highly ordered chromatin structure that 
makes homology search difficult (Branzei and Foiani 2008). 
 
Checkpoints can either trigger arrest of cell cycle progression (G1, S or G2 
phase) or trigger the induction of necessary repair genes. The cell cycle arrest 
allows the repair of genetic material thereby preventing secondary lesions and 
ensuring the appropriate progression into the next phase of the cycle (Meeran 
and Katiyar 2008). Checkpoint signaling may also result in activation of 
pathways leading to programmed cell death if cellular damage cannot be 
properly repaired. Defects in cell cycle checkpoints can result in gene 
mutations, chromosome damage, and aneuploidy, all of which can contribute to 
tumour genesis (Pietenpol and Stewart 2002). 
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The G1 and G1/S checkpoint 
The acquisition of abnormalities at the G1/S checkpoint appears to be the most 
crucial step in the genesis and progression of cancer. Therefore, in the 
presence of DNA damage, the G1/S checkpoint prevents replication of 
damaged DNA through several distinct signal transduction pathways. Upon 
such a DNA damage, the activated Chk1 phosphorylates Cdc25A, which 
triggers its ubiquitination and degradation by the proteasom pathway and this 
abrogates G1/S transition.  
p53 is one of the most important cell cycle proteins modulated by regulation of 
Checkpoint G1. Inactivation of p53 pathway as well pRb at the G1/S transition is 
a fundamental requirement for the genesis of most human cancers. 
Transcriptional responses by p53, for example through phosphorylation and 
acetylation, are then required for maintaining the G1/S arrest. Phosphorylation 
of p53 causes an accumulation of p35 protein in the nucleus by inhibiting its 
nuclear export and degradation. Usually p53 is dormant until activated by DNA 
damage or other genomic aberrations. The key transcriptional target of p53 is 
the Cip1/p21. This allows DNA repair or the induction of various pro-apoptotic 
factors.  
 
 
Figure 3: The G1/S checkpoint (Pietenpol and Steward 2002) 
 
Negative regulation of G1 phase cyclin/Cdk complexes plays a key role in the 
G1/S checkpoint function. Cdks are negatively regulated by prior described Cdk 
inhibitors, which hence play regulatory roles during G1/S cell cycle checkpoint. 
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For example, after exposure of normal cells to genotoxic agents, p21Waf/Cip1 is 
induced by p53-dependent transactivation. The elevated p21 binds and 
inactivates cyclin D/Cdk4,6 and Cyclin D/Cdk2 complexes resulting in pRb 
hypophosphorylation and cell cycle arrest (figure 3) (Pietenpol and Stewart 
2002). 
 
Thus, the G1 checkpoint signals target two independent and critical tumor 
suppressor pathways, governed by p53 and pRb, which are most commonly 
deregulated in human cancers (Meeran and Katiyar 2008). 
 
The S-phase checkpoint 
The intra-S-phase checkpoint link functions to avoid the duplication of damaged 
or broken DNA which would eventually lead to genomic instability. 
This checkpoint is regulated by two distinct pathways, named 
(1) ATM/ATR-Chk1-Cdc25A and  
(2) ATM-Nbs1-SMC1.  
Ad 1) Depending on the type of DNA damage, ATM or ATR phosphorylates 
Chk1 which in turn phosphorylates Cdc25A. In response to genotoxic stress, 
the activity of Chk1 and Chk2 is enhanced. This leads to a down regulation of 
Cdc25A what in turn causes inactivation of Cyclin E-Cdk2.  
Ad 2) This type of intra-S-Checkpoint reflects the impact of ATM-mediated 
phosphorylation of Nbs1 on several sides. It is required for activation of the 
Nbs1-Mre11-Rad11-Rad50 complex. Depending on the phosphorylation state of 
Nbs, the cohesin protein SMC1 is phosphorylated on Ser957 and Ser966 by 
ATM, which is required for the intra-S checkpoint.  
These two kinds of intra-S-checkpoints have been documented in response to 
both ionizing radiation and UV radiation. Other proteins that are involved in the 
intra-S checkpoint too are for example 53BP1, BRCA1, FANCD2 and MDC1 
(Meeran and Katiyar 2008). 
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The G2/M checkpoint 
The G2/M checkpoint prevents cells from entering into mitosis when they 
experience DNA damage during G2 or when they carry unrepaired DNA from 
G1 or S to progress into G2 through inhibiting Cyclin B/Cdc2.  
 
 
Figure 4: G2 checkpoint response after genotoxic stress (Pietenpol and Steward 2002) 
 
The maintenance phase of G2/M partially relies on the transcriptional programs 
regulated by BRCA1 and p53. p53-dependent mechanisms are also important 
for the maintenance of G2 arrest following DNA damage.  
After DNA damage, members of the PI-3K family 
become activated and directly phoshporylate p53, 
including DNA-PK, ATM and ATR. ATM-
dependent signaling induced by DNA damage 
also results in activation of Chk1 and Chk2 
kinases, which mediate phosphorylation of p53. 
This is important for stabilization of the protein 
after DNA damage. After ATM-dependent 
activation, Chk1 and Chk2 also phosphorylate 
Cdc25C and Ser-216 and that furthermore 
generate a consensus binding site for 14-3-3 
proteins. This inhibits Cdc2 activity (Pietenpol 
and Stewart 2002). 
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Figure 5: G2 checkpoint response after genotoxic stress (Pietenpol and Steward 2002) 
 
p53 at G2/M phase works in three ways: 
(1) Through p21, GADD45, which causes the dissociation of the Cdc2 and 
cyclin B/Cdc2 complex 
(2) Through 14-3-3 sigma, which sequesters the cyclin B/Cdc2 complex in 
the cytoplasm and 
(3) Through repression of the transcription of Cdc2 and Cyclin B 
(Meeran and Katiyar 2008) 
 
2.2. Cell death programs 
 
Homeostasis is maintained in multicellular organisms by a balance between cell 
proliferation and cell death. There are three major morphologies of cell death:  
• apoptosis (type I) 
• cell death associated with autophagy (type II) 
• necrosis (type III). 
Almost every dying or dead cell have the same final fate, namely engulfment by 
phagocytes. This clearance process (figure 6) is very important for the 
development and homeostasis. A defective or inefficient clearance may 
contribute to several human pathologies, for example systemic lupus 
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erythemotosus, cystic fibrosis and chronic obstructive pulmonary disease 
(Krysko et al. 2007). 
An important feature of currently used anti-cancer drugs is their potential to 
trigger programmed cell death (apoptosis) and to inhibit cell cycle progression. 
This, it is relevant to investigate whether cell cycle inhibition and apoptosis-
induction becomes initiated by novel anti-cancer drugs, because these 
mechanisms are required to regulate tissue homeostasis, but frequently escape 
proper function in cancer cells. 
 
 
 
2.2.1. Apoptosis 
Cells undergoing apoptosis show typical, well-defined morphological changes, 
like plasma membrane blebbing, chromatin condensation with margination of 
chromatin to the nuclear membrane, karyorhexis (nuclear fragmentation), and 
formation of apoptotic bodies (Krysko et al. 2007). 
 
There are two different types of apoptosis: 
1) Caspase-dependent apoptosis  
2) Caspase-independent apoptosis 
 
Fig. 6: A scheme of internalization 
mechanisms used by 
macrophages to engulf apoptotic 
and necrotic cells. (Krysko et al. 
2007) 
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Fig.7: Similar, distinct, and overlapping triggers of apoptosis I and apoptosis II (Huettenbrenner 
et al. 2003) 
 
Ad 1) Apoptotic cell death involves the orchestrated action of catabolic 
enzymes, like proteases and nucleases, within the limits of intact plasma 
membranes. It is accompanied by a characteristic change of nuclear 
morphology and chromatin biochemistry (stepwise DNA degradation). 
Caspases cleave their targets after aspartic acid residues and catalyze a highly 
selective pattern of protein degradation. Moreover, cellular organelles remain 
morphologically intact (only subtle changes of like partial protein degradation 
become manifest), whereas cells shrink and reduce intracellular potassium 
level.  
Ad2) Execution of apoptotic chromatin degradation is not only achieved by 
executioner caspases and their effector CAD but also by AIF in a caspase-
independent fashion. AIF activates a nuclear DNAse which cuts genomic DNA 
into 50 kb fragments giving rinse to a distinct nucleo-morphological phenotype 
of chromatin condensation, the so-called stage I. Whereas CAD generates the 
phenotype of stage II chromatin condensation. 
 
The two mechanisms of apoptosis execution exist together and may cooperate. 
It needs to be determined whether either of the pathways can be triggered 
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separately depending on the cell type, the context, or the stimulus 
(Huettenbrenner et al. 2003). 
 
2.2.2. Autophagy 
Cells undergoing death associated with autophagy are characterized by the 
presence of double membrane autophagic vacuoles. Cells deprived of nutrient 
or obligate growth factors foremost activate autophagy. When cellular stress 
continuous, cell death may continue by autophagy alone. Alternatively it often 
comes associated with features of apoptotic or necrotic cell death (Krysko et al. 
2007). 
 
2.2.3. Necrosis 
Necrosis is characterized by rapid cytoplasmic swelling and in the end a rupture 
of the plasma membrane and organelle breakdown. Necrosis has long been 
described as a consequence of extreme physicochemical stress, such as heat, 
somatic shock, mechanical stress, freeze thawing and high concentration of 
hydrogen peroxide. Because of the quick death due to the prior conditions, 
necrosis has been described as accidental and uncontrolled. However, many 
different cellular stimuli (TNF on certain cell lines, dsRNA, IFN-γ, ischemia) have 
been shown to induce necrosis. This induced necrotic cell death results from 
extensive cross-talk between several biochemical and molecular events at 
different cellular levels and it is as controlled and programmed as apoptosis. It 
is important to distinguish necrosis from other forms of cell death, because it is 
often associated with an unwarranted loss of cells in human pathologies. 
Furthermore it can also lead to local inflammation because of the release of 
intracellular factors from death cells, the so-called damage associated 
molecular pattern that alert the innate immune system (Krysko 2008). 
 
2.2.4. Apoptosis-necrosis: similar start-different finish 
Multiple stresses or physiological induction causes ion reflux of the 
mitochondrial pore transition (PT). Thereby the mitochondrial membrane 
potential ∆Ψm disturbs and in consequence an interference with mitochondrial 
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oxidative phosphorylation resulting in the decrease of ATP takes place. Due to 
the osmotic pressure, H2O and Ca2+ ions cause swelling of the cytoplasm and 
organelles. Finally the cells burst and spill the fluid into the pericellular space. 
This phenomenon describes a classic necrotic phenotype. Another 
consequence of a disrupted ∆Ψm is the uncoupling of the respiratory chain. This 
lead to the hyperproduction of ROS, affection of the plasma potential, and 
subsequent irreversible oxidation of thiols and membrane lipids, as well as the 
depletion of glutathione. 
 
Cytochrome C together with Apaf1 (both are released through the PT-pore 
complex) induces caspase 9, which directly translocates into the nucleus to 
induce caspase-independent stage I apoptosis.  
Very likely, AIF exerts its activity during apoptosis and necrosis. Therefore, the 
extent of ∆Ψm disturbance may determine between life and deaths as a point of 
no return.  
 
Figure 8: Apoptosis-necrosis: similar start-different finish (Halestrap 2002) 
 
The PT-pore complex is controlled by Bcl-2 and Bcl-KL and upon extopic 
overexpression. Bcl-2 inhibits PT and prevents both apoptosis and necrosis. 
Thus, early apoptotic onset and necrosis start with similar events such as PT. 
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Bcl-2 regulate another component of the PT-pore complex, called ANT. ANT 
exchanges mitochondrial matrix ATP for cellular ADP. ATP:ADP ratio 
determines whether a cell will vanish by necrosis or apoptosis. For example, 
noxious stimuli like stress or toxic compounds cause an ATP depletion and 
therefore necrosis. Exhausted ATP in consequence of excessive trauma blocks 
the apoptotic execution machinery downstream of PT and necrosis prevails.  
 
However, the necrosis-apoptosis decision is not only taken by ATP. An example 
is a specific inhibition of caspases by z-VAD-fmk. This renders cells to exit by a 
necrotic phenotype although identical stimuli induce apoptosis when z-VAD-fmk 
is omitted.  
 
Therefore, the status of ∆Ψm which depends on stress type and impact, not only 
switches between life and death, but gives also major directives for death 
modes such as necrosis, type II apoptosis, and caspase-independent apoptosis 
by AIF (Huettenbrenner et al. 2003). 
 
2.3. Cancer 
 
Tumours are complex tissues composed of ever-evolving neoplastic cells, 
matrix proteins that provide structural support and sequester biologically active 
molecules, and a cellular stromal component. Reciprocal interactions between 
neoplastic cells, activated host cells and the dynamic micro-environment in 
which they live enable tumour growth and dissemination (Van Kempen et al. 
2006). 
 
2.3.1. Basics of cancer development 
Central to the development of cancer are genetic changes that endow these 
“cancer cells” with many of the hallmarks of cancer, such as self-sufficient 
growth and resistance to anti-growth and pro-death signals. However, while the 
genetic chances that occur within cancer cells themselves, such as activated 
oncogenes or dysfunctional tumour suppressors, are responsible for many 
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aspects of cancer development, they are not sufficient. Tumour promotion and 
progression are dependent on ancillary themselves.  
Cancer results from the outgrowth of a clonal population of cells from tissue. 
The development of cancer, referred to as carcinogenesis, can be modelled and 
characterized in a number of ways. One way to describe this process is to 
illustrate the essential features of both cancer cells and tumours: the “hallmarks” 
of cancer (next chapter).  
 
Cancer can also be considered with regard to a step-wise development 
functionally grouped into three phases: initiation, promotion and progression.  
 
Figure 9: Multistage carcinogenic model (Harris 1991) 
 
Initiation is characterized by genomic changes within the “cancer cell” such as 
point mutations, gene depletion and amplification, and chromosomal 
rearrangements leading to irreversible cellular changes. Tumour development is 
promoted by the survival and clonal expansion of these “initiated” cells. 
Progression encompasses a substantial growth in tumor size and either growth-
related or mutually exclusive metastasis (Rakoff-Nahoum 2006). 
 
The development of cancer in humans involves a complex succession of events 
that usually occur over many decades. During this multistep process, the 
genomes of incipient cancer cells acquire mutant alleles of proto-oncogenes, 
tumor-suppressor genes, and other genes that control, directly or indirectly, cell 
proliferation. Different combinations of these mutant alleles are found in the 
genomes of many distinct types of human cancer a well as in different cancers 
from the same tissue. An ever-increasing number of these genes have been 
shown to make contributions to the distinct steps involved in neoplastic 
transformation. The complexity of these observations provokes the question of 
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whether these genes and the more than 100 distinct types of human cancer can 
ever be rationalized in terms of a small number of underlying biologic and 
biochemical principles. Recent successes in the experimental transformation of 
human cells indicate that the disruption of a limited number of cellular regulatory 
pathways is sufficient to impart a tumourgenic phenotype to a wide variety of 
normal cells. These results, in turn, suggest a series of genetic and cellular 
principles that may govern the formation of most, if not all, types of human 
cancers (Hahn and Weinberg 2008). 
 
2.3.2. The six hallmarks of Cancer 
In the past decades researches revealed a small number of molecular, 
biochemical and cellular traits, the so called acquired capabilities. There are six 
essential alterations in cell physiology that collectively dictate malignant growth: 
 
 
Figure 10: Six essential alterations in cell physiology (Hanahan and Weinberg 2000) 
 
These traits can be found in most or perhaps all types of human cancer, 
because virtually all mammalian cells carry similar machinery, which regulates 
their proliferation, differentiation and death.  
 
1. Self-sufficiency in growth signals 
2. Insensitivity to growth-inhibitory 
(antigrowth) signals 
3. Evasion of programmes cell death 
(apoptosis) 
4. Limitless rexplicative potential 
5. Sustained angiogenesis 
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Genetic alterations are responsible for the transformation of normal cells into 
highly malignant derivates. These cancer cells have defects in regulatory 
circuits that govern normal cell proliferation and homeostasis. 
 
Self-Sufficiency in Growth Signals 
Normal cells require mitogenic growth signals (GS) before they can move from 
a quiescent state into an active proliferative state. Many of the oncogenes act 
by mimicking these normal growth signals. 
All tumour cells are able to synthesize their own growth signals hence they 
show a greatly reducted dependence on exogenous growth stimulation, thereby 
reducing their microenvironment. They may create a positive feedback 
signalling loop that often termed autocrine stimulation.  
 
But there are some other ways to loose dependency. For example receptor 
overexpression may enable the cancer cell to become hyper responsive to 
ambient levels of growth factors that normally do not trigger proliferation. 
Furthermore the ability of cancer cells to switch the types of extra cellular matrix 
receptors which they express, favouring ones that transmit progrowth signals, is 
another alternative too.  
 
Moreover integrin receptor can bind to specific moieties of the extracellular 
matrix. This enables the transduction from signals into the cytoplasm and this 
influence cell behaviour, ranging from quiescence in normal tissue to motility, 
resistance to apoptosis and entrance into the active cell cycle.  
 
Finally tumour cells are able to co-opt their normal neighbours by inducing them 
to release abundant fluxes of growth-stimulation signals either through direct 
contact or through secreted signal-molecules.  
 
Insensitivity to Antigrowth Signals 
Within a normal tissue, multiple antiproliferative signals are situated which 
maintain cellular quiescence and tissue homeostasis. Such signals are soluble 
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growth inhibitors and immobilized inhibitors. There are two distinct mechanisms 
whereby antigrowth signals can block proliferation:  
1. Cells may be forced out of the active cycle into the quiescent (G0) state. 
Not until extra cellular signals permit, they may remerge in the future.  
2. Cells have the ability to relinquish their proliferative potential by being 
induced to enter into post mitotic states. This was usually associated with 
acquisition of specific differentiation-associated traits.  
Incipient cancer cells must evade these antiproliferative signals if they are to 
prosper.  
One opportunity is to disrupt the pRb pathway, through that many and perhaps 
all antiproliferative signals are funnelled. That will lead to liberation of E2Fs and 
thus allows cell proliferation, rendering cells insensitive to antigrowth factors. 
These factors normally operate along this pathway to block advance through 
the G 1 phase of the cell cycle.  
 
In addition, cancer cells are able to turn of expression of integrins and other cell 
adhesion molecules that send antigrowth signals, particularly those that convey 
progrowth signals.  
 
Cell proliferation depends on more than an avoidance of cytostatic antigrowth 
signals. Our tissue also constrains cell multiplication. It may instruct cells to 
enter irreversibly into post mitotic, differentiated states by using diverse 
mechanisms that are incompletely understood. However it’s apparent that 
tumour cells use various strategies to avoid this terminal differentiation.  
 
Evading Apoptosis 
The ability of tumour cell populations to expand in number is determed by rate 
of cell proliferation and by the rate of cell attrition, for what apoptosis represents 
a major source. Therefore resistance toward apoptosis is a hallmark of most 
and perhaps all types of cancer. 
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The discovery of the bcl-2 oncogene by its upregulation via chromosomal 
translocation in follicular lymphoma and its recognition as having antiapoptotic 
activity opened up the investigation of apoptosis in cancer at the molecular 
level. A cell’s apoptotic program can be triggered by an overexpression of 
oncogene. Indeed, elimination of cells bearing activated oncogenes by 
apoptosis may represent the primary means by which such mutant cells are 
continually culled from the body’s tissues. Collectively, observations argue that 
altering components of the apoptotic machinery can dramatically affect the 
dynamics of tumour progression, providing a rationale for the inactivation of this 
machinery during tumour development.  
Resistance to apoptosis can be acquired by cancer cells through a variety of 
strategies. The most commonly occurring loss of a proapototic regulator through 
mutation involves the p53 tumor suppressor gene. The resulting functional 
inactivation of its product, the p53 protein, is seen in greater than 50% of human 
cancers and results in the removal of a key component of the DNA damage 
sensor that can induce the apoptotic effector cascade. Signals evoked by other 
abnormalities, including hypoxia and oncogene hyper expression, are also 
funnelled in part via p53 to the apoptotic machinery; these too are impaired at 
eliciting apoptosis when p53 function is lost. Additionally, the PI3 kinase 
AKT/PKB pathway, which transmits antiapoptotic survivals signals, is likely 
involved in tumours.  
We expect that virtually all cancer cells harbour alterations that enable evasion 
of apoptosis.  
 
Limitless Replicative Potential 
Many or perhaps all types of mammalian cells carry an intrinsic, cell-
autonomous program that limits their multiplication. A disruption of this program 
causes expansion of cell to a size that constitutes a macroscopic, life 
threatening tumour.  
 
Cells in culture have a finite explicative potential. This can be avoided by 
disabling their pRb and p53 tumor suppressor protein. This follow massive cell 
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death, caryotypic disarray associated with end-to-end fusion of chromosomes 
and even the occasional emergence of variant (1 in 107) cells that has acquired 
the ability to multiply without limit.  
 
The counting device for cell generation, the so-called telomeres, is composed of 
several thousand repeats of a short 6 bp sequence element. During each cell 
cycle telomeric DNA loses 50-100 bp. Therefore cells lose their ability to protect 
the ends of chromosomal DNA and finally the affected cell dies. Hence, 
telomere maintenance is evident in virtually all types of malignant cells. There 
are two different possibilities how cells can protect their telomere: 
1. Upregulation of expression of the telomerase enzyme, by adding 
hexanucleotide repeats onto the ends of telomeric DNA 
2. Activating a mechanism – termed ALT – which appears to maintain 
telomeres through recombinant-based interchromosomal exchanges of 
sequence information 
Therefore telomere maintenance is a clearly key component of the capability for 
unlimited replication, but another one, the circumvention of cellular senescence 
is undetermined. 
 
Sustained Angiogenesis 
The vasculature is crucial for the supply of oxygen und nutrients. All cells in a 
tissue reside within 100 µm of a capillary blood vessel. A coordinated growth of 
vessels and parenchyma ensured this closeness during organogenesis. 
Because cells within aberrant proliferative lesions initially lack angiogenesis 
ability, incipient neoplasias must develop angiogenic ability.  
 
Counterbalancing positive and negative signals encourage, like endothelial 
growth factor (VEGF) and acidic or basic fibroblast growth factors (FGF1/2), or 
block, like thrombospondin-1, angiogenesis. Tumour may activate the 
angiogenic switch by changing the balance of these angiogenesis inducers and 
countervailing inhibitors, for example through altered gene transcription. 
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Integrin signaling contributes to this regulatory balance too, while quiescent 
vessel expresses one class of integrins and sprouting capillaries express 
another. Interference between these classes of integrins can inhibit 
angiogenesis. 
 
Another way to regulate angiogenesis is proteases, which can control the 
bioavailability of angiogenic activators and inhibitors.  
 
Tissue Invasion and Metastasis 
Primary tumour masses of most types of human cancer spawn pioneer cells 
that move out and invade adjacent issue. Then they travel to distend sites 
where they may succeed in founding new colonies. In effect these distant 
settlements of tumour cells, called metastasis, are the cause of 90 % of human 
cancer deaths. Invasion and metastasis are exceedingly complex processes, 
and their genetic and biochemical determinants remain incompletely 
understood.  
 
There are several classes of proteins that possess invasive or metastatic 
capabilities. These proteins are involved in tethering of cells to their 
surroundings in a tissue are altered in cells. The affected proteins include cell-
cell adhesion molecules (CAMs), for example E-cadherin expressed on 
epithelial cells, and integrins, which link cells to extra cellular matrix substrates. 
All of these “adherence” interactions convey regulatory signals to the cell. 
Changes in expression of CAMs and integrins play a critical role in the 
processes of invasion and metastasis, such as forced expression of integrin 
subunits in cultured cells can induce or inhibit invasive and metastatic 
behaviour.  
 
The second general parameter of the invasive and metastatic capability 
involves extra cellular proteases. Some proteases are characteristically 
associated with the cell surface. Thereby they facilitate invasion by cancer cells 
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into nearby stoma, across blood vessel walls and through normal epithelial cell 
layers.  
 
The activation of extra cellular proteases and the altered binding specificities of 
cadherin, CAMs and integrins are clearly central to the acquisition of 
invasiveness and metastatic ability. But the regulatory circuits and molecular 
mechanisms that govern these shifts remain elusive and, at present, seem to 
differ from one tissue environment to another (Hanahan and Weinberg 2000). 
 
2.3.3. Cancer and Inflammation 
An association between the development of cancer and inflammation has long-
been appreciated (Rakoff-Nahoum 2006). Recent data have expanded the 
concept that inflammation is a critical component of tumour progression. Many 
cancers arise from sites of infection, chronic irritation and inflammation 
(Coussens and Werb 2002). 
 
Epidemiologic studies estimate that nearly 15 percent of the worldwide cancer 
incidence is associated with microbial infections. For example, chronic infection 
in immunocompetent hosts such as human papilloma virus or hepatitis B and C 
virus infection leads to cervical and hepatocellular carcinoma. Or conditions 
associated with chronic irritation and subsequent inflammation predispose to 
cancer, such as the long-term exposure to cigarette smoke, asbestots and silica 
(Rakoff-Nahoum 2006). 
 
It has become evident that early and persistent inflammatory responses 
observed in or around developing neoplasm’s regulates many aspects of 
tumour development, like matrix remodelling, angiogenesis and malignant 
potential, by providing diverse mediators implicated in maintaining tissue 
homeostasis, e.g., soluble growth and survival factors, matrix remodelling 
enzymes, reactive oxygen species and other bioactive molecules (Van Kempen 
et al. 2006). 
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In addition, tumour cells have co-opted some of the signalling molecules of the 
innate immune system, such as selectins, chemokines and their receptors for 
invasion, migration and metastasis. These insights are fostering new anti-
inflammatory therapeutic approaches to cancer development (Coussens and 
Werb 2002). 
 
2.3.4. Leukaemia 
The first cell line which was used to perform the experiments was HL-60 
promyelocytic leukaemia cells. Leukaemia is a blood or bone marrow cancer 
and is characterized by an abnormal proliferation of blood cells, mostly 
leukocytes. Leukaemias are a heterogeneous group of haematopoietic 
malignancies that include many diverse and biologically distinct subgroups. The 
four major subtypes of leukaemia described by most cancer registries include 
acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic 
lymphoblastic leukaemia (CLL), and chronic myeloid leukaemia (CML) (Yang et 
al. 2003). The leukaemia show clear geographic, racial, ethnic, age, and gender 
variation in both incidence and mortality. The patterns of occurrence differ 
among subtypes. Known risk factors are ionizing, radiation, certain 
chemotherapeutic agents, and specific occupational chemical exposures. Some 
risk factors like infections agents, electromagnetic fields, cigarette smoking, 
other chemotherapeutic agents, and additional occupational chemical expose 
are suspected in leukemogenis (Groves et al. 1994). 
 
2.3.5. Breast cancer 
The second used cell line was MCF-7 breast cancer cells, which are frequently 
used in pharmacological studies. Cancer of the breast is the most common 
cancer in women worldwide. Around 1.15 million cases were recorded in 2002, 
accounting for around 23 per cent of all cancers in women (11 per cent overall). 
Observed rates of this cancer increase with industrialisation and urbanisation, 
and also with facilities for early detection. It remains much more common in 
high-income countries (figure11) but is now increasing rapidly in middle- and 
low-income countries, including Africa, much of Asia, and Latin America.  
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Figure 11: Age standardist (world) incidence and mortaly rates, female breast cancer in selectet 
countries, 2002 estimates; UK Breast Cancer incidence statistics 
 
Breast cancer is fatal in under half of all cases and is the leading cause of death 
from cancer in women (fifth overall), accounting for 14 per cent of all cancer 
deaths worldwide. Breast cancer is hormone related, and the factors that modify 
the risk of this cancer when diagnosed premenopausally and when diagnosed 
(much more commonly) postmenopausally are not the same. There is evidence 
showing the importance of early life events, including food and nutrition, as well 
as factors that affect hormone status, in modification of the risk of breast cancer 
(World Cancer Research Fund 2007). 
 
2.3.6. Nutrition and Cancer 
Food and nutrition modify the risk of cancers at a large number of sites. 
Vegetables, fruits, pulses (legumes), nuts, and seeds are sources of a wide 
variety of micronutrients and other bioactive compounds. Foods containing 
several of these constituents have been identified as being associated with 
cancer risk. However, it is not possible to ascribe the association between these 
foods and lower cancer risk to a causal effect of specific compounds with 
confidence, because each food contains a complex mixture of different 
constituents, all of which might also contribute to any effect (World Cancer 
Research Fund 2007). 
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Food components relevant to cancer development can be divided into macro- 
and micro components. The former tend to act indirectly. The latter usually have 
a clearly defined action, for example as genotoxic agents. Food can have both 
positive (carcinogenic) and negative (preventive) effects (Sugimura 2002). 
For example, Quercetin is a flavonoid, which is a type of polyphenol. It is not an 
essential dietary component. Many studies in cultured cells and animals 
suggest that quercetin has antioxidant activity, which could lead to a range of 
biological activities, including reducing inflammation. Quercetin is found in 
apples, green and black tea, onions, raspberries, red wine, red grapes, citrus 
fruits, cherries, elderberries, broccoli, blueberries, cranberries, bilberries, and 
leafy, green vegetables, such as L. sativa  (World Cancer Research Fund 
2007). 
 
2.4. Drugs 
 
2.4.1. Overview 
Many chemotherapeutic strategies interfere with important steps in cell cycle 
progression such as DNA replication and repair. Induction of apoptosis is 
another indicator for drug activity in cancer cells. However, the key drawback is 
that these drugs often cause sever side effects including immunotoxicity, 
neurotoxicity and nephrotoxicity.  
 
Human tumour implanted animal models are often used for selecting anti-
cancer drugs in drug discovery. The problems of in vivo models are, on the one 
hand, the long experimental duration, high costs and on the other hand, the 
limited predictive values because of species variations and other factors. That’s 
why alternative methods such as in vitro cell-based assays, genomics and 
computational assays have gained more attention. Cultured human tumour 
cells, in our case HL 60 leukaemia cells and MCF-7 breast cancer cells, have 
been used as in vitro screening tools for identifying cancer drugs. Although 
activity oriented assays have been the major approaches of finding target-
specific cancer drugs, minimizing toxic effects is also crucial to the development 
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of successful cancer drugs. It is recognized that understanding of toxicological 
properties in early phase will help to realise the bottlenecks and accelerate 
drugs discovery (W. Li et al. 2006). 
In our particular case, the feature of nonspecific toxity and undesired side 
effects is minimized because the tested plants have a long history of being used 
and well tolerated in humans.  
 
2.4.2. Development of drugs 
 
The development of new medical products usually begins with basic research 
not knowing about any toxic side effects. Hence we selected two healing plants, 
which are still used by the Maya of the Guatemala/Belize lowland rain forest 
thereby eliminating the feature of non-specific toxity. These plants are known to 
be successful in healing chronical inflammations and to be well tolerated by 
humans (in terms of side effects) and are unknown in the western medicinal and 
experimental literature (i.e. listed in PubMed) 
The next step is the preclinical development. My part of this project was to study 
the possible in vitro anticancer activity of two plants which are used in traditional 
medicine to treat inflammations, because inflammation involves the activation of 
enzymes and intracellular pathways which may be also upregulated in tumour 
cells. In the traditional application the plants are air-dried which is a time-
consuming process in the humid climate of the tropics and this may cause the 
degradation of active metabolites. From previous investigations with A. 
alopecuroidea we know that freeze-drying of plants is mandatory for the 
preservation of their anti-cancer activity. Therefore, we compared the effectivity 
of the traditional- versus a modern preparation methods (freeze-drying of freshly 
harvested plants).  
 
Further investigation would imply more preclinical test, the clinical development 
and end with a potential approval (in Europe through the „Richtlinie 2001/83/EG 
des Europäischen Parlaments und des Rates vom 6. November 2001 zur 
Schaffung eines Gemeinschaftskodexes für Humanarzneimittel“, in the USA 
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from the US Food and Drug Administration FDA) Finally the product could be 
launched.  
 
 
Figure 12: Development of new medical products (DE, investigational device exemption) 
(Gutman et al. 2006) 
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3. MATERIAL AND METHODS 
 
3.1. Plants 
 
3.1.1. Syngonium podophyllum (Contra Hierba) 
 
  
Figure 13 : Syngonium podophyllum Figure 14 : Syngonium podophyllum 
  (http://sweetgum.nybg.org/common/imagedisplay.php?irn=181951) 
 
Kingdom: Plantae 
Division: Magnoliophyta 
Class: Liliopyida 
Order: Alismatales 
Family: Araceae 
Genus: Syngonium 
Species: Syngonium podophyllum 
 
Syngonium is a genus of 33 species in the family Araceae. To this family belong 
107 genuses and over 3700 species. The parasitic vine grows on trees in forest 
clearings from Mexico to Panama. It can reach up to 5 m in length. In the adult 
form the large leaves are deeply lobed. The fruits are red. When a stem or a 
leave breaks it exudes a sticky latex.  
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Traditional Uses: 
A warm wash with leaves from S. podophyllum is used against sore, dry skin, 
fungus, itching, rashes and bruises. For rheumatism, arthritis, swellings and 
general pains a tincture of leaves soaked in alcohol is rubbed on painful areas.  
The important compounds are calcium oxalate and oxalic acid (Arvigo and 
Balick 1998). 
 
3.1.2. Pluchea Odorata (Santa Maria) 
 
 
   
 
 
 
Kingdom: Plantae 
Division: Magnoliophyta 
Class: Rosopsida 
Subclassis: Asteridae 
Order: Asterales 
Family: Asteracae 
Genus: Pluchea 
Species: Pluchea odorata 
Figure 15 Pluchea odorata 
(www.fp.sfasu.edu) 
Figure 16: Pluchea odorata 
(www.delawarewildflowers.org) 
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Asteracea is the largest family of the order of the asterales. To this family 
belong 1528 genuses and 22750 species and it grows worldwide in every clime. 
The habitat of P. odorata are clearings, old fields and the edges of forests. It is 
a woody shrub up to 3 m of height with many branches. Like most species of 
this family the plant has aromatic leaves and brownish green flowers in large 
heads, turning to orange.  
Traditional Uses: 
A tea, made by boiling 3 P. odorata leaves in 3 cups of water for 2 minutes 
followed by 15 minutes of steeping, is used as a treatment against asthma 
attacks, coughs, colds and flu. A poultice with leaves warmed in oil should help 
against sore muscles, rheumatic pains, neuritis and arthritic joints. Furthermore 
P. odorata is used against infections and excessive bleedings after childbirth. 
Therefore the women sit over a steaming pot of herbs. Swelling, tumors, 
inflammations and bruises are also bathed in this herbal decoction (Arvigo and 
Balick 1998). The important compound of this plant is plucheinol. 
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3.1.3. Lactuca sativa var. capitata (Lettuce - Green salad) 
 
   
 
 
 
Kingdom: Plantae 
Division: Magnoliophyta 
Class: Magnoliopsida 
Order: Asterales 
Family: Asteraceae 
Subfamily: Cichorioideae 
Genus: Lactuca 
Species: Lactuca sativa 
Form: Lactuca sativa var. capitata 
 
Lettuce is a cultivated form of L. sativa, which originally comes from neaples. 
The leaves are very compact and even after preparation very firm. Raw lettuce 
is used for salad and hamburgers, tacos and other dishes. In some countries 
lettuce is eaten cooked too. 
 
Figure 17. L. sativa 
(http://en.wikipedia.org/wiki/) 
40/97 
 
3.2. Plant-extraction 
 
The plants P. odorata and S. podophyllum were brought from Guatemala (San 
José/Petén). From these two plants I had two different materials: 
Syngonium podophyllum 
- air dried stipes and roots 
- lyophilized stipes and roots from fresh plants 
Pluchea odorata 
- air dried leaves, florescence and stipes 
- lyophilized leaves from fresh material 
L. sativa was bought at a market in Vienna and afterwards lyophilized too.  
The extractions were done in Prof. Dr. Brigitte Kopp’s laboratory. (Department 
of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna) 
 
First, the plant parts were milled (RETSCH ZM 100, sieve Nr. 05) and the 
obtained powder was weight out. Afterwards solvent was added with a 
concentration of 1:10 (to 50 g dried plant material 500 ml of e.g. petroleum ether 
was added). The solvent treated plant material (starting with the molst apolar 
solvent, PE) was dried for subsequent extractions with increasingly polar 
solvents. This methodical procedure is state of the art because it provides an 
initial seperation of apolar to polar bioactive plant constituents thereby providing 
maximal information by minimum plant expense. 
Solvent Reflux - water bath (°C) Rotary evaporator (mbar) 
Petroleum ether 40 650 
Dichlormethan 50 650 
Ethyl acetate 91 200 
Methanol 79 300 
Water 111 65 
Table 1: solvents and the specific temperature and pressure used for the evaporator 
The plant powder together with solvent was treated in an ultra sonic bath for 10 
minutes to burst the cells of the plant. Then it was situated on a reflux – water 
bath. The temperature depends on which solvent was taken (shown in table 1). 
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After 60 minutes the solvent was filtered through a round filter (Schleicher & 
Schuell, Microscience, 595, RefNr. 10311612 – diameter 150 nm).  
o The remaining plant material (residue) was dried on a sheet of paper to 
complete dryness before the next extraction with a more polar solvent 
followed (from petroleum ether to water). 
o The material which was dissolved in the liquid phase (solvent) was 
gained by evaporating the solvent until complete dryness using a 
rotavapor (Heidolph WB 2001) with a temperature of the water bath 
(Heidolf VV 2011) of 40°C. The pressure is shown in table 1.  
So step by step five plant extracts (PE extract, CH2Cl2 extract, EA extract, 
MeOH extract and water extract) were obtained. Finally the dried extracts were 
dissolved in ethanol for further use in cell culture experements.  
 
3.3. Cell Culture 
 
HL-60 promyelocytic leukaemia cells, MCF-7 breast cancer cells and MCF-10A 
immortalized non-tumorigenic fibrocystic mammary gland epithelial cells were 
purchased from ATCC. HL-60 cells were grown in logarithmical growth phase in 
RPMI 1640 medium, MCF-7 and MCF-10A in DMEM medium, all of them 
supplemented with 10% heat inactivated fetal calf serum, 1% L-Glutamine and 
1% Penicillin/Streptomycin at 37°C in a humidified atmosphere containing 5% 
CO2. All media and supplements were obtained from Life Technologies. All cell 
types were kept in humidified atmosphere containing 5 % CO2 at 37°C. 
 
Figure 18: untreated HL-60 cells 
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3.4. Proliferation-Assay 
 
Three different cell types were used: HL-60, MCF-7 and MCF-10A. To 
determine the antiproliferative effect of the plant extracts HL-60 cells were 
seeded in T-25 tissue culture flasks at a concentration of 0.1 x 106 cells per ml. 
MCF-7 and MCF-10A were seeded at a concentration of 0.01 x 106 cells per ml 
in 24-well plates and grown for 24 h. Then they were incubated with increasing 
concentration of plant extracts (500 µg/ml, 1 mg/ml, 4 mg/ml, 20 mg/ml) for 72 
h. After 24 h and 72 h cells were counted and IC50 values for plant extracts were 
determined with a microcellcounter (Sysmex Corp., Japan). MCF-7 and MCF-
10A had to be washed with PBS and trypsinised before. Experiments were 
done in triplicate.  
 
Calculation to determine the percent of cell division: 
[(C72 h + drug – C24 + drug)/(C72 – drug – C24 h – drug)] x 100 = % cell division 
 
C72h + drug ? cell number after 72 hours of drug treatment 
(specific for the resprective extract concentrations) 
C24h + drug ? cell number after 24 hours of drug treatment 
(specific for the resprective extract concentrations) 
C72h – drug ? cell number after 72 houres without drug treatment 
C24 h – drug ? cell number after 24 hours without drug treatment 
 
3.5. Apopotose Assay – Hoechst 33258/propidium iodide (HOPI) 
double staining 
 
To determine the type of cell death, HL-60 cells were seeded in T-25 tissue 
culture flasks (0.1 x 106 cells per ml) and MCF-7 were seeded in 24-well plates 
(0.01 x 106 cells per ml), grown for 24 h and treated with increasing 
concentrations (500 µg/ml, 1 mg/ml, 4 mg/ml, 20 mg/ml) of extract for 96 h. 
Afterwards MCF-7 cells were washed with PBS and trypsinised. Then Hoechst 
and propidium iodide were added directly to the cells at a final concentration of 
5 µg/ml and 2 µg/ml for 1 hour at 37°C and then the stained cells were 
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photographed on Kodak Ektachrome P1600 film, analysed and counted 
manually. Experiments were done in triplicate. 
 
3.6. FACS-analysis 
 
HL-60 cells were seeded in T-25 tissue culture flaks with a concentration of 1 x 
106 cells per ml and incubated with 500 µg/ml and 1 mg/ml Pluchea odorata 
dichlormethan extract at 37°C under cell culture conditions for 24 hours. Then 
the cells were washed with cold PBS, centrifuged (900 rpm, 5 min), 
resuspended and fixed in EtOH (70%) for 30 min at 4°C. After two further 
washing steps with cold PBS, RNASe A and propidium iodide were added to a 
final concentration of 50 µg/ml each, incubated at 4°C over night and 
determined by FACSCalibur flow cytomenter (BD Bioscience, San Jose, CA, 
USA). Cell distribution was calculated with ModFid LT software (Verity Software 
House, Topsham, ME, USA)  
 
3.7. Western blotting 
 
Preparation of lysates 
HL 60 cells were seeded in T-25 tissue culture flasks at a concentration of 1x 
106 cells per ml and incubated with 4 mg/ml extract (P. odorata and L. sativa) 
for 0.5, 1, 4, 8 and 24 hours. At every time point, 2x106 cells were harvested, 
washed twice with cold PBS, centrifuged at 1000 rpm for 5 minutes and lysed in 
100 µl buffer (containing 150 nM NaCl, 50 mM Tris pH 8.0, 1% Triton-X-100), 5 
µl 1 mM phenylmethylsulfonylfluorid (PMSF) and 5 µl Protease Inhibitor Cocktail 
(PIC; from a 100 x stock). Afterwards the lysate was centrifuged for 20 min at 
12000 rpm at 4°C, and the supernatant was stored at –20°C until further 
analyses.  
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SDS-PAGE and electrotransfer 
Equal amounts of lysate (protein samples) were loaded onto a polyarylamide 
gels. Proteins were electrophoresed (PAGE) and then electro-blotted onto 
PVDF-membranes (Hybond- Amersham) at 20 V 4°C overnight or at 90 V for an 
hour (both at 4°C). To confirm equal sample loading, membranes were stained 
with Ponceau S. 
  
Figure 19: Membran stained with Ponceau S 
 
Immuno-reaction 
After washing with PBS/T (Phosphate Buffered Saline/0,5% Tween 20, pH: 7.2) 
or TBS/T (Tris Buffered Saline/0,1% Tween 20, pH: 7.6) the membranes were 
blocked in PBS- or TBS-Milk (5% non-fat dry milk in PBS containing 0.5% 
Tween or in TBS containing 0.1% Tween 20) for one hour and then washed 
with PBS/T or TBS/T for at least 30 min changing the washing solution 3-4 
times. Afterwards the membranes were incubated with the first antibody (in 
blocking solution, dilution 1:500) by gently rocking at 4°C overnight. Then the 
membranes were washed with PBS/T or TBS/T for 30 min and incubated with 
the second antibody (anti-rabbit IgG or anti-mouse IgG, dilution 1:2000) for 1 
hour at room temperature. After washing with PBS/T or TBS/T the chemo 
luminescence was detected by ECL detection kit (Amersham, UK) and the 
membranes were exposed to Amersham Hyper films.  
  
Antibodies: 
o Cyclin D1 (M-20) :sc-718, polyclonal (SANTA CRUZ BIOTECHNOLOGY; 
INC) 
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o P21 (C-19) :sc-397, polyclonal (SANTA CRUZ BIOTECHNOLOGY, INC) 
o Phospho-p44/42 MAP Kinase (Thr202/Tyr204) E10, #9106, monoclonal 
(Cell Signaling) 
o P44/42 MAP Kinase (137F5) Rabbit, #4695, monoclonal (Cell Signaling) 
o Phospho-MEK 1/2 (Ser21/221), #9121, polyclonal (Cell Signaling) 
o MEK 1/2 AB, #9122, polyclonal (Cell Signaling) 
o Cleaved Caspase-3 (Asp175), #9661, polyclonal (Cell Signaling) 
o PARP-1 (F-2): sc-8007, monoclonal (SANTA CRUZ BIOTECHNOLOGY, 
INC) 
o MONOCLONAL ANTI-ACETYLATED TUBULIN, CLONE 6-11B-1, 
Mouse Ascited Fluid, Product No. T6793 (SIGMA) 
o α Tubulin (DM1A): sc-32293, monoclonal (SANTA CRUZ 
BIOTECHNOLOGY, INC) 
o β Tubulin (H-235): sc-9104, polyclonal (SANTA CRUZ 
BIOTECHNOLOGY, INC) 
o Monoclonal Anti-β-Actin, Clone AC-15, mouse ascites fluid, Catalog 
Number A5441 (SIGMA) 
o Cdc25A (phospho S17) antibody (ab18321), polyclonal (abcam) 
o Phospho-cdc25a-S177 Antibody, polyclonal (ABGENT) 
o Cdc25A (F-6): sc-7389, monoclonal (SANTA CRUZ BIOTECHNOLGOY, 
INC) 
o Cdc25A (M-191): sc-7157, polyclonal (SANTA CRUZ 
BIOTECHNOLOGY, INC) 
o Phospho-Chk2 (Thr68), #2661, polyclonal (Cell Signaling) 
o Chk2 Antibody, #2662, polyclonal (Cell signaling) 
o Phospho-cdc2 (Tyr15) (10A11) Rabbit mAb, #4539, monoclonal (Cell 
Signaling) 
o Phospho-Chk1 (Ser345), #2341, polyclonal (Cell Signaling) 
o Chk1, #234 (Cell Signaling) 
Pierce EC Western Blotting Substrate Cat #32106 (Pierce) 
Amersham Hyper films ECL – High performance chemiluminnescence film (GE-
Helthcare) 
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3.8. COX Inhibitor Screening Assay 
 
Cyclooxygenase (COX, also called Prostagladin H Synthase or PGHS) 
enzymes catalyze the first step in the biosynthesis of prostagladins (PG´s), 
thromboxanes, and prostacylin; the conversion of arachidonic acid to PGH2.  
COX-2 is believed to be the target enzyme for the anti-inflammatory activity of 
nonsteroidal anti-inflammatory drugs.  
This assay measures PGF2α produced by SnCl2 reduction of COX-derived 
PGH2. 
The COX screening assay was purchasead from CAYMAN (Catalog No. 
560131) and performed according to the manufactures instructions. 
 
Performing COX-Reaction 
Reagenses: Reaction Buffer, COX-2 human recombinant, Heme, Arachidonic 
acid, Potassium hydroxide, Hydrochloric acid, Stannous Chloride 
• Background tubes: Inactive COX-2 (COX-2 3 min in boiling water) was 
mixed with heme 
• COX-2 100 % Initial activity tubes: COX-2 was mixed with heme 
• COX-2 Inhibitor tubes: COX-2 was mixed with heme and afterwards 
extracts, derived from freeze dried stipes and roots from Syngonium 
podophyllum, were added in different concentrations (0,01 mg/ml; 0,1 
mg/ml; 1 mg/ml; 4 mg/ml) 
? Incubation for 10 minutes at 37°C (on water bath) 
 
COX-reaction was initiated by adding 10 µl of arachidonic acid to all test tubes 
following a further incubation for 2 min at 37°C water bath. Adding 1 M HCl 
stopped catalysis. To obtain a more stable prostaglandin saturated stannous 
chloride solution was added to each test tube (this reagens reduce PGH2 to 
PGF2α). 
Prostaglandins are quantified by EIA.  
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Performing the EIA 
Regencies: EIA Buffer, Wash Buffer, Prostaglandin Standard, Prostaglandin 
Screening AchE Tracer, Prostaglandin Screening Antiserum 
Each COX-reaction was assayed at two dilutions and each dilution was 
assayed in triplicate. Blanks, non-specific binding wells, maximum binding wells, 
total activity wells, Background samples (COX-2) and eight point standard curve 
(Prostaglandin Standard) were performed in duplicate. Afterwards the plate was 
covered with plastic film and incubated for 18 hours at room temperature. 
 
Development and reading the plate 
The plate was emptied and then washed five times. Ellmans´s Reagents was 
added and the plate was covered with plastic film again. Now the plate was 
developed in the dark by using a shaker for 90 minutes and then was readed at 
a wavelength of 405 nm. 
 
3.9. Total phenolics determination 
 
Total phenolic content was determined using the Folin-Ciocalteu method, 
described by Singleton et al. and slightly modified according to Dewanto et al. 
125 µl of suitable diluted extracts and 125 µl Folin-Ciocalteu reagent were 
merged. Afterwards 0.5 ml deionized water was added. The mixture was kept 
for 6 min, and then, 1.25 mL of a 7% aqueous Na2CO3 solution was added. The 
final volume was adjusted to 3 mL with water. After 90 min, the aborbtion was 
measured at 760 nm against water as a blanc. The amount of total phenolics 
was expressed as gallic acid equivaltents (GAE, mg gallic acid/100 g sample) 
through the calibration curve of gallic acid (Heimler et al. 2007). 
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4. RESULTS 
 
4.1. Syngonium Podophyllum 
 
The first tested plant was S. Podophyllum. Two different parts of this plant were 
analysed: 
 
• stipes and roots – lyophilized 
• stipes and roots – air dried 
 
4.1.1. Stock calculation 
4.1.1.1. Stipes and roots – lyophilized 
Table 2a shows the extract weight in g derived from 51.6 g freeze dried plant of 
the five different solvent types (petroleum ether, dichlormethan, ethyl acetate, 
methanol, water) and the extract amount corresponding to 1 mg plant.  
 
Four different concentrations were used to perform proliferation assays: 500 
µg/ml, 1 mg/ml, 4 mg/ml and 20 mg/ml. The supplied extracts were added as 
shown in table 2b.  
 
a) 
Solvent Extract weight (g) 
Derived from 51,6 g dried plant 
Extract 
corresponding to 
1mg plant 
Petroleum Ether 0.44132 8.55 µg 
Dichloromethane  0.13854 2.68 µg 
Ethyl Acetate 0.23121 4.48 µg 
Methanol 2.57482 48.90 µg 
Water 2.14285 41.53 µg 
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b) 
Extract Type  Concentration 
mg dried plant weight/ml 
medium 
µg dried extract weight/ml 
medium 
0.5 4.28 µg
1 8.55 µg
4 34.20 µg
Petroleum 
Ether 
20 171 µg
0.5 1.34 µg
1 2.68 µg
4 10.72 µg
Dichlormethane 
20 53.60 µg
0.5 2.24µg
1 4.48 µg
4 17.92 µg
Ethyl Acetate 
20 89.60 µg
0.5 24.45 µg
1 48.90 µg
4 195.60 µg
Methanol 
20 978.00 µg
0.5 20.77 µg
1 41.53 µg
4 166.12 µg
Water 
20 830.60 µg
c)  
PE 3 ml EtOH 
CH2Cl2 3 ml EtOH 
EA 3 ml EtOH 
MeOH 4 ml EtOH and 2 ml MeOH 
H2O 13 ml H2O 
Table 2: Extract weights from 51.6 g dried plant 
 
The plant extracts were dissolved in different amounts of ethanol, methanol or 
water (see table 2 c). To avoid solvent bias, EtOH was added to the control and 
every other concentration to achieve similar solvent concentrations as in the 
highest extract concentration (20 mg/ml) e.g. for petroleum ether (in 5 ml 
Medium): 
? For control: ad 5.81 µl EtOH 
? For 500 µg/ml: ad 5.66 µl EtOH (5.81-0.15) 
? For 1 mg/ml: ad 5.52 µl EtOH (5.81-0.29) 
? For 4 mg/ml: ad 4.65 µl EtOH (5.81-1.16) 
In general, this corresponded to an ethanol-concentration of 0.12% in every 
sample.  
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4.1.1.2. Stipes and roots – air dried 
Table 3a shows the extract weight in g derived from 43.8 g air dried plant for 
the five different solvent types (petroleum ether, dichlormethan, ethyl acetate, 
methanol, water) and the extract amount corresponding to 1 mg plant.  
 
Four different concentrations were used to perform proliferation assays: 500 
µg/ml, 1 mg/ml, 4 mg/ml and 20 mg/ml. The supplied extracts were added as 
shown in table 3b.  
 
a) 
Solvent Extract weight (g) 
Derived from 43.80 g 
dried plant 
Extract corresponding to 
1mg plant 
Petroleum Ether 0.43452 9.92 µg 
Dichloromethane  0.36114 8.25 µg 
Ethyl Acetate 0.2309 5.27 µg 
Methanol 1.51751 34.65 µg 
Water 2.60450 59.46 µg 
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b) 
Extract Type  Concentration 
mg dried plant weight/ml 
medium 
µg dried extract weight/ml medium
0.5 4.96 µg
1 9.92 µg
4 39.68 µg
Petroleum Ether 
20 198.40 µg
0.5 4.13 µg
1 8.25 µg
4 33.00 µg
Dichlormethane 
20 165.00 µg
0.5 2.64 µg
1 5.27 µg
4 21.08 µg
Ethyl Acetate 
20 105.40 µg
0.5 17.33 µg
1 34.65 µg
4 138.60 µg
Methanol 
20 693.00 µg
0.5 29.73 µg
1 59.46 µg
4 237.84 µg
Water 
20 1189.20 µg
c) 
PE 4 ml EtOH 
CH2Cl2 3 ml EtOH 
EA 3 ml EtOH 
MeOH 4 ml EtOH and 2 ml MeOH 
H2O 18 ml H2O 
Table3: Extract weights from 43.80 g dried plant 
 
The plant extracts were dissolved in different amounts of ethanol, methanol or 
water (see table 3 c). To avoid solvent bias, EtOH was added to the control and 
every other concentration to achieve similar solvent concentrations as in the 
highest extract concentration (20 mg/ml) e.g. for dichlormethan (in 5 ml 
Medium): 
? For control: ad 6.85 µl EtOH 
? For 500 µg/ml: ad 6.68 µl EtOH (6.85-0.17) 
? For 1 mg/ml: ad 6.51µl EtOH (6.85-0.34) 
? For 4 mg/ml: ad 5.48 µl EtOH (6.85-1.37) 
In general, this corresponded to an ethanol-concentration of 0.14% in every 
sample.  
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4.1.2. Antiproliferative activity of S. podophyllum extracts 
All extracts were tested in HL-60 cells. As illustrated in figure 20 all extracts 
showed an antiproliferative activity in HL-60 cells at a concentration of 20 
mg/ml. The potential of the air dried material is rather similar to that of the 
freeze dried material regarding proliferation inhibitory effects. In both extract 
types methanol extract was the most effective with a growth inhibition of 80 % at 
a concentration of 4 mg/ml. Furthermore the dichlormethan extract has a 
comparatively high antiproliferative effect too with an inhibition of 30 % at a 
concentration of 4 mg/ml. All of the other extracts (petroleum ether, 
dichlormethan, ethyl acetate and water) showed an effective growth inhibition 
up to nearly 90 % at a concentration of 20 mg/ml.  
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Figure 20 legend: Anti-proliferative effects of air dried and freeze dried S. podophyllum  
HL-60 cells were seeded into T-25 tissue culture flasks (1 x 105 cells / ml), grown for 24 hours to 
enter logarithmic growth phase, and incubated with 0.5, 1, 4, and 20 mg/ml of plant extracts 
(mg-amounts relate to freeze dried alternatively dried plant material before extractions). 
Controls received around 0.2% EtOH which was the ethanol concentration which cells had to 
experience together with the highest extract concentration. The other samples were also 
adjusted to equal ethanol concentrations to achieve similar solvent conditions. Cells were 
counted after 24, 48 and 72 hours of treatment and the percentage of proliferation between this 
time span was calculated in comparison to controls (controls were considered as 100 % 
proliferating cells and all other conditions were set in relation to this). Experiments were done in 
triplicate. Error bars indicate SEM, and asterisks significant proliferation inhibition compared to 
control (p<0.05).  
 
Plant material Solvent IC 50 
S. podophyllum Stipes and roots Lyophilized Petroleum ether n.r.
S. podophyllum Stipes and roots Lyophilized Dichlormethan 9.5 mg/ml
S. podophyllum Stipes and roots Lyophilized Ethyl acetate n.r.
S. podophyllum Stipes and roots Lyophilized Methanol 2.6 mg/ml
S. podophyllum Stipes and roots Lyophilized Water 16 mg/ml
S. podophyllum Stipes and roots Air dried Petroleum ether 12.5 mg/ml
S. podophyllum Stipes and roots Air dried Dichlormethan 11.5 mg/ml
S. podophyllum Stipes and roots Air dried Ethyl acetate 17 mg/ml
S. podophyllum Stipes and roots Air dried Methanol 2.7 mg/ml
S. podophyllum Stipes and roots Air dried Water 14.7 mg/ml
n.r. = not reached 
Table 4: IC 50 - values of S. podophyllum 
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4.1.3. Anti-inflammatory activity evaluated as PGH2 
The extract with the hightest antiproliferative activity of S. podophyllum was 
freeze dried methanol. Therefore this extract was used to perform this assay, 
but the results weren´t significant. That´s why they were not shown at this place. 
 
Since the anti-proliferative activity was rather low and the anit-inflammatory 
activity didn´t exist, we skipped further analyses with this plant. 
 
4.2. Pluchea odorata 
 
The more effective of the two tested plants was P. odorata. Two different parts 
of this plant were analysed: 
 
• leaves, lyophilized 
• leaves, florescence and stipes, air dried 
 
4.2.1. Stock calculation 
4.2.1.1. Leaves - lyophilized 
Table 5a shows the extract weight in g derived from 35.8 g freeze dried plant 
for the five different solvent types (petroleum ether, dichlormethan, ethyl 
acetate, methanol, water) and the extract amount corresponding to 1 mg plant.  
 
Four different concentrations were used to perform proliferation and apoptosis 
assays: 500 µg/ml, 1 mg/ml, 4 mg/ml and 20 mg/ml. The supplied extracts 
were added as shown in table 5b.  
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a) 
Solvent Extract weight (g) 
Derived from 35.8 g dried plant 
Extract corresponding to 1mg plant
Petroleum Ether 0.97193 27.15 µg 
Dichloromethane  0.9580 26.76 µg 
Ethyl Acetate 0.46451 12.98 µg 
Methanol 6.26163 174.91 µg 
Water 3.9381 110.00 µg 
b) 
Extract Type  Concentration 
mg dried plant weight/ml medium 
µg dried extract weight/ml medium 
0.5 13.76 µg
1 27.15 µg
4 108.60 µg
Petroleum 
Ether 
20 543.00 µg
0.5 13.38 µg
1 26.76 µg
4 107.04 µg
Dichlormethane 
20 535.20 µg
0.5 6.49 µg
1 12.98 µg
4 51.92 µg
Ethyl Acetate 
20 259.60 µg
0.5 87.46 µg
1 174.91 µg
4 699.64 µg
Methanol 
20 3498.20 µg
0.5 55.00 µg
1 110.00 µg
4 440.00 µg
Water 
20 2200.00 µg
c) 
PE 4 ml EtOH 
CH2Cl2 5 ml EtOH 
EA 3 ml EtOH 
MeOH 4 ml EtOH and 4 ml MeOH 
H2O 8 ml H2O 
Table 5: Extract weights from 35.80 g dried plant 
 
The plant extracts were dissolved in different amounts of ethanol, methanol or 
water (see table 5 c). To avoid solvent bias, EtOH was added to the control and 
every other concentration to achieve similar solvent concentrations as in the 
highest extract concentration (20 mg/ml) e.g. for ethyl acetate (in 5 ml Medium): 
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? For control: ad 8.38 µl EtOH 
? For 500 µg/ml: ad 8.17µl EtOH (8.38-0.21) 
? For 1 mg/ml: ad 7.96 µl EtOH (8.38-0.42) 
? For 4 mg/ml: ad 6.70 µl EtOH (8.38-1.68) 
In general, this corresponded to an ethanol-concentration of 0.17% in every 
sample.  
 
4.2.1.2. Leaves, florescence and stipes - air dried 
Table 6a shows the extract weight in g derived from 38.75 g air dried plant for 
the five different solvent types (petroleum ether, dichlormethan, ethyl acetate, 
methanol, water) and the extract amount corresponding to 1 mg plant.  
 
Four different concentrations were used to perform proliferation assays: 500 
µg/ml, 1 mg/ml, 4 mg/ml and 20 mg/ml. The supplied extracts were added as 
shown in table 6b.  
 
a) 
Solvent Extract weight (g) 
Derived from 38.75 g dried plant 
Extract corresponding to 1mg 
plant 
Petroleum Ether 0.6015 15.52 µg 
Dichloromethane  0.27748 7.16 µg 
Ethyl Acetate 0.10966 2.83 µg 
Methanol 1.014 26.17 µg 
Water 3.1978 82.52 µg 
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b) 
Extract Type  Concentration 
mg dried plant weight/ml medium 
µg dried extract weight/ml 
medium 
0.5 7.76 µg
1 15.52 µg
4 62.08 µg
Petroleum Ether 
20 310.40 µg
0.5 3.58 µg
1 7.16 µg
4 28.64 µg
Dichlormethane 
20 134.20 µg
0.5 1.42 µg
1 2.83 µg
4 11.32 µg
Ethyl Acetate 
20 56.60 µg
0.5 0.39 µg
1 0.77 µg
4 3.08 µg
Methanol 
20 15.40 µg
0.5 41.26 µg
1 82.52 µg
4 330.08 µg
Water 
20 1650.40 µg
c) 
PE 3 ml EtOH 
CH2Cl2 3 ml EtOH 
EA 3 ml EtOH 
MeOH 3 ml EtOH and 3 ml MeOH 
H2O 13 ml H2O 
Table 6: Extract weights from 38.75 g dried plant 
 
The plant extracts were dissolved in different amounts of ethanol, methanol or 
water (see table 6 c). To avoid solvent bias, EtOH was added to the control and 
every other concentration to achieve similar solvent concentrations as in the 
highest extract concentration (20 mg/ml) e.g. for petroleum ether (in 5 ml 
Medium): 
? For control: ad 5.16 µl EtOH 
? For 500 µg/ml: ad 5.03 µl EtOH (5.16-0.13) 
? For 1 mg/ml: ad 4.90 µl EtOH (5.16-0.26) 
? For 4 mg/ml: ad 4.13 µl EtOH (5.16-1.03) 
In general, this corresponded to an ethanol-concentration of 0.1 % in every 
sample.  
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4.2.2. Anti-proliferative activity of P. odorata extracts 
All extracts showed an antiproliferative effect in HL-60 cells (figure 21). A 
concentration of 4 mg/ml caused 95 to 100 % proliferation in every extract type. 
Unexpectedly, the way of plant drying did not affect the activity of the P. odorata 
dichloromethane extract, because air-dried and freeze-dried plant material 
arrested the cell cycle similarly and at low doses.The best result showed the 
dichlormethan extract with a growth inhibition of 80 % at a concentration of 1 
mg/ml. Therefore a proliferation assay was made in MCF-7 breast cancer cells 
too. These cells are frequently used in pharmacological studies, because the 
vast majority of all agents, which exhibit activity in the NCI-60 cell line screen, 
are also active in MCF-7 breast cancer cells (Cragg 2000). Furthermore a 
proliferation assay in MCF-10A breast epithelial cells was also made. 
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Figure 21 legend: Anti-proliferative effects of P. odorata and L. sativa extracts  
HL-60 cells were seeded into T-25 tissue culture flasks (1 x 105 cells / ml), grown for 24 hours to 
enter logarithmic growth phase, and incubated with 0.5, 1, 4, and 20 mg/ml of plant extracts 
(mg-amounts relate to dried plant material before extractions). Controls received 0.10% to 
0.45% EtOH which was the ethanol concentration which cells had to experience together with 
the highest extract concentration. The other samples were also adjusted to equal ethanol 
concentrations to achieve similar solvent conditions. Cells were counted after 24 and 48 hours 
of treatment and the percentage of proliferation between this time span was calculated in 
comparison to controls (controls were considered as 100 % proliferating cells and all other 
conditions were set in relation to this). MCF-7 and MCF-10A cells were seeded in 24 well plates, 
allowed to attach for 24 hours when extracts were applied as described above and cells 
counted after 24, 48, and 72 hours. Experiments were done in triplicate. Error bars indicate 
SEM, and asterisks significant proliferation inhibition compared to control (p<0.05).  
60/97 
 
Both cells types caused a growth inhibition of 100 % at 4 mg/ml (figure 21). 
MCF-7 showed an antiproliferative activity of 10 %, MCF-10A of 25%. That’s 
however less efficient than observed in HL-60 cells. As a negative control the 
dichlormethanextract of L. sativa was tested, because this is not a 
pharmacological plant that can be consumed in considerable amounts. 4 mg/ml 
dichlormethan extract of L. sativa was non-toxic. Unexpectedly, the 20 mg/ml 
concentration (corresponding to 320 µg dried extract/ml) exhibited significant 
anti-proliferative activity. This evidences that the anti-proliferative properties of 
L. sativa was not an effect of random plant toxicity or due to extremely high 
residue amounts in the L. sativa dichlormethan extract, but specific due to 
unknown apolar constituents. 
 
Plant material Solvent IC 50 
P. odorata Leaves Lyophilized Petroleum ether 2 mg/ml
P. odorata Leaves Lyophilized Dichlormethan 0.7 mg/ml
P. odorata Leaves Lyophilized Ethyl acetate 1.8 mg/ml
P. odorata Leaves Lyophilized Methanol 2.4 mg/ml
P. odorata Leaves Lyophilized Water 2.2 mg/ml
P. odorata Leaves, florescence 
and stipes 
Air dried Petroleum ether 2 mg/ml
P. odorata Leaves, florescence 
and stipes 
Air dried Dichlormethan 0.8 mg/ml
P. odorata Leaves, florescence 
and stipes 
Air dried Ethyl acetate 3 mg/ml
P. odorata Leaves, florescence 
and stipes 
Air dried Methanol 9.6 mg/ml
P. odorata Leaves, florescence 
and stipes 
Air dried Water 3.3 mg/ml
Table 7: IC 50 - values of P. odorata 
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4.2.3. Dichlormethan extract of P. odorata inhibits cell cycle in G2-M 
HL-60 cells were seeded in T-25 tissue culture flaks with a concentration of 1 x 
106 cells per ml and incubated with 500 µg/ml, and 1 mg/ml P. odorata 
dichlormethan extract at 37°C under cell culture conditions for 24 hours. Then 
the cells were stained and the respective cell cycle phase cell distribution was 
determed by FACS analysis. 
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Figure 22: Cell cycle distribution of HL 60 cells upon treatment with of P. odorata 
dichloromethane extract  
Logarithmically growing HL-60 cells were incubated with increasing concentrations of 0.5 and 
1.0 mg/ml extract for 24 hours and then subjected to FACS analysis. Error bars indicate SEM 
and asterisks significance regarding the respective cell cycle phase of untreated controls (p = 
0.05). Experiments were done in triplicate.  
 
Figure 22 shows a significant increase in cells inhibited at the G2-M-Phase in 
the cell cycle progression with a higher number of cells in G2-M-Phase and 
lesser number of cells in S-Phase. Furthermore the quantity of pre-G1-Phase-
cells growth up to 10 % at a concentration of 1 mg/ml.  
 
4.2.4. Inhibition of proliferation is preceded by the down-regulation of cell 
cycle protagonists 
Deregulated cell cycle progression is a hallmark of cancer. Cyclin-dependent 
kinases (CDK) play central roles in promoting cell cycle progression. 
Overexpression of CDK phosphatases often occurs in human cancer because 
uncontrolled activation of CDK´s as well down-regulation of CDK´s is the driving 
force of cancer cell proliferation. CDC 25 phosphatases are critical for timely 
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CDK activation in cell cycle progression. Studies using cultured cells suggest 
that CDC 25A regulates both G1-S and G2-M transition (Ray and Kiqokawa 
2008) Chk2 was shown to target Cdc 25A to proteasomal degradation and 
therefore inhibit cell cycle.  
4 mg/ml dichlormethane extract of P. odorata caused an activating 
phosphorylation of Chk 2 (figure 23a) after 2 hours followed by a decrease of 
Cdc 25A within 24 hours of incubation. 
Cyclin D1 is an important regulator of G1 to S phase progression. 
Overexpression of cyclin D1 has been linked to the development and 
progression of cancer. Deregulated Cyclin D1 degradation appears to be 
responsible for the increased level of Cyclin D 1 in several cancers. Therefore 
Cyclin D1 is an attractive targent for anti-cancer therapy (Alao 2007). Figure 
23a shows that Cyclin D1 expression decreased after 8 hours too. P. odorata 
did not induce p21, a cell cycle inhibitor, but constitutive p27 expression 
became suppressed. This did not correlate with cell cycle inhibition.  
 
On the other hand 4 mg/ml dichlormethanextract of L. sativa showed no effect 
in HL-60 proliferisation, neither with cdc25 nor with Cyclin D1 or p27. 
 
a) 
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b) 
  
Figure 23 legend: Analysis of cell cycle-related protein and phospho-protein expression  
HL-60 cells (1x106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for  24 
hours when cells were incubated with 4 mg/ml dichloromethane extract of P. odorata and L. 
sativa for 0.5, 2, 4, 8, and 24 hours. Then, isolated protein samples were subjected to 
electrophoretic separation and subsequent Western blot analysis using antibodies against:  
(a) Cdc25A, phospho-Thr68-Chk2, Chk2, cyclin D1, p27; (b) phospho-Thr202/Tyr204-Erk, and 
Erk. Equal sample loading was controlled by Poinceau S staining and β-actin analysis. 
 
Erk (MAP-Kinase) plays a critical role in the regulation of cell growth and 
differentiation. It is a major transducer of mitotic signalling. Figure 23b shows 
that Erk became dephosphorylated and therefore inactivated after 8 hours of 
treatment.  
L. sativa dichlormethan extract showed an intense and long-lasting 
phosphorylation after 2 hours. In contrast, the prior presented Proliferation 
assay hasn’t shown this effect. Therefore, the level of Erk did not correlate with 
the proliferation of HL-60 cells  
 
4.2.5. The dichlormethan extract of P. odorata induces caspase 3 and 
apoptosis 
The dichlormethan extract of P. odorata was further tested regarding pro-
apoptotic properties in HL-60 and MCF-7 cells because a major of cytotoxic 
anticancer drugs is the potential to elicit cancer cell death. Both cell types 
induced apoptosis, in HL-60 earlier than in MCF-7. A concentration of 4 mg/ml 
was sufficient to eliminate 100 % of HL60-cells after 48 hours. MCF-7 cells 
caused a cell death rate of 85 % after 96 hours (figure 24). 
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Figure 24 legend: Induction of apoptosis and necrosis by the dichloromethane extract of P. 
odorata 
HL-60 cells were incubated for 48 hours and MCF-7 cells for 96 hours with increasing extract 
concentrations. Then, cells were double stained with Hoechst 33258 and propidium iodide and 
examined under the microscope with UV light connected to a DAPI filter. Nuclei with 
morphological changes which indicated apoptosis or necrosis (see “Methods”) were counted 
and percentages of vital, apoptotic and necrotic cells were calculated. Experiments were done 
in triplicate. Error bars indicate SEM, and asterisks significant apoptosis induction compared to 
control (p<0.05).  
 
Caspases are the most important enzymes for apoptosis. Initiator caspases, like 
Caspase-8 and Caspase-9, cleave downstream pro-form caspases (Caspase 
3/7/6). In HL-60 cells Caspase 3 becomes activated by P. odorata extract. 
Caspase-3 plays a key role during apoptosis. It is totally or partially responsible 
for the proteolytic cleavage of many key proteins such as the nuclear enzyme 
poly (ADP-ribose) polymerase (PARP) (Fernandes-Alnemri et al. 1994). 
As we have seen in prior figures, that dichlormethanextract of P. odorata starts 
to induces apoptosis at a concentration of 1 mg/ml in HL-60 cells. At a 
concentration of 4 mg/ml and 24 hour we see a distinctive cleavage of Caspase 
3 to 19 kDa and 12 kDa, which is indicative for its activation. 4 mg/ml of the 
dichlormethan extract of L. sativa has no effect, Caspase 3 wasn’t cleaved and 
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apoptosis was not induced. This antibody detects only the activated form at 19 
kDa, but not full length caspase-3 or other cleaved caspases.  
 
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that is activated by 
DNA strand breaks to participate in DNA repair (Pieper et al. 1999). Activated 
Caspase 3 cleaves the 116 kDA death substrate PARP into an 85 kDa 
fragment. Figure 24 shows that PARP was cleaved after 24 hour P. odorata 
incubation, hence caspase 3 activation starts before PARP signature type 
cleavage, thereby evidencing that Caspase-3 was in fact functional. Therefore, 
it’s safe to say that P. odorata triggers apoptotic cell death executed by 
Caspase-3. In contrast, the dichlormethanextract of L. sativa did not induce cell 
death in HL-60 or MCF-7 cells.  
 
  
Figure 25 legend: Western blot analysis of pro-apoptotic Caspase 3 and its target PARP 
HL-60 cells (1x106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for 24 
hours when cells were incubated with 4 mg/ml methanol extract derived from P. odorata and L. 
sativa for 0.5, 2, 4, 8, and 24 hours. Then isolated protein samples were subjected to 
electrophoretic separation and subsequent Western blot analysis using antibodies against: 
Caspase 3 which recognizes only the cleavage product indicating caspase activation, PARP 
which recognizes the full length form (116 kDa) and the signature-type cleaved product (85 
kDa) which is generated by active Caspase 3.  Equal sample loading was controlled by 
Poinceau S staining and β-actin analysis.  
 
Tubulin is a major cytoskeleton component that has three distinct forms, α, β 
and γ-tubulin. α- and β-Tubulin compose a tubulin heterodimer, which 
multimerize to form a microtubule filament. They undergo a variety of post-
translational modification, which may affect microtubule stability and protein 
interaction.  
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Microtubules are implicated in a variety of cellular functions including mitosis, 
intracellular transport, the maintenance of cell shape, and the formation of 
motile systems such as eukaryotic cilia and flagella (Piperno and Fuller 1985).  
The first tested antibody was directed against acetylated α-tubulin, because this 
protein could regulate the presence of microtubule in specific intracellular 
spaces by selective stabilization (Piperno et al. 1987). P. odorata dichlormethan 
extract (4 mg/ml) induced the acetylation of α-tubulin after 30 minutes, which 
intensified till 4 and remained for 24 hours.  
 
a) b) 
 
Figure 26 legend: Western blot analysis of tubulin acetylation 
HL-60 cells (1x106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for 24 
hours when cells were incubated with 4 mg/ml methanol extract derived from (a) P. odorata and 
(b) 1 µM paclitaxel for 2, 4, 8, and 24 hours. Then, isolated protein samples were subjected to 
electrophoretic separation and subsequent Western blot analysis using antibodies against: 
acetylated-α-tubulin, α-tubulin, and β-tubulin. Equal sample loading was controlled by Poinceau 
S staining and β-actin analysis.  
 
Therefore, this extract type stabilises microtubule, such as taxol. Taxol is a 
major anti-cancer drug derived form the genus Taxa sp. The effectiveness of 
this drug is that it permits an increased acetylation, like P. odorata too, and this 
causes mitotic arrest and in consequence apoptosis. 
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4.3. Lactuca sativa 
 
4.3.1. Stock calculation 
Finally freeze dried L. sativa was analysed. Table 8a shows the extract weight 
in g derived from 18.8 g freeze dried plant for the five different solvent types 
(petroleum ether, dichlormethan, ethyl acetate, methanol, water) and the extract 
amount corresponding to 1 mg plant.  
 
Four different concentrations were used to perform proliferation assays: 500 
µg/ml, 1 mg/ml, 4 mg/ml and 20 mg/ml. The supplied extracts were added as 
shown in table 8b.  
 
a) 
Solvent Extract weight (g) 
Derived from 18.8 g dried plant 
Extract corresponding 
to 1mg plant 
Petroleum Ether 0.29398 15.64 µg 
Dichloromethane  0.30170 16.05 µg 
Ethyl Acetate 0.23782 12.65 µg 
Methanol 3.23782 172.22 µg 
Water 2.57090 136.75 µg 
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b) 
Extract Type  Concentration 
mg dried plant weight/ml medium
µg dried extract weight/ml medium
0.5 7.82 µg
1 15.64 µg
4 62.56 µg
Petroleum Ether 
20 312.80 µg
0.5 8.03 µg
1 16.05 µg
4 64.20 µg
Dichlormethane 
20 321.00 µg
0.5 6.25 µg
1 12.65 µg
4 50.60 µg
Ethyl Acetate 
20 253.00 µg
0.5 86.11 µg
1 172.22 µg
4 688.88 µg
Methanol 
20 3444.40 µg
0.5 68.38 µg
1 136.75 µg
4 547.00 µg
Water 
20 2735.00 µg
c) 
PE 1.5 ml EtOH 
CH2Cl2 1.5 ml EtOH 
EA 1 ml EtOH 
MeOH 1 ml EtOH and 1.5 ml MeOH 
H2O 8 ml H2O 
Table 8: Extract weights from 18.80 g dried plant 
 
The plant extracts were dissolved in different amounts of ethanol, methanol or 
water (see table 8 c) To avoid solvent bias, EtOH was added to the control and 
every other concentrations to achieve similar solvent concentrations as in the 
highest extract concentration (20 mg/ml) e.g. for dichlormethan (in 5 ml 
Medium): 
? For control: ad 7.98 µl EtOH 
? For 500 µg/ml: ad 7.78 µl EtOH (7.98 -0.20) 
? For 1 mg/ml: ad 7.8 µl EtOH (7.98-0.40) 
? For 4 mg/ml: ad 6.38 µl EtOH (7.98-1.60) 
In general, this corresponded to an ethanol-concentration of 0.16 % in every 
sample.  
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4.3.2. Anti-proliferative activity of L. sativa extracts 
Overall it’s evident that all extracts showed a growth inhibition at a 
concentration of 20 mg/ml (Figure 27). The antiproliferative effect in HL-60 cells 
was higher than in MCF-7 cells. The best result could be achieved in HL-60 as 
well as MCF-7 cells with the water extract. The inhibition was around 50 % at a 
concentration of 4 mg/ml.  
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Figure 27 legend: Anti-proliferative effects of L. sativa extracts  
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HL-60 cells were seeded into T-25 tissue culture flasks (1 x 105 cells / ml), grown for 24 hours to 
enter logarithmic growth phase, and incubated with 0.5, 1, 4, and 20 mg/ml of plant extracts 
(mg-amounts relate to dried plant material before extractions). Controls received 0.1% to 0.3% 
EtOH which was the ethanol concentration which cells had to experience together with the 
highest extract concentration. The other samples were also adjusted to equal ethanol 
concentrations to achieve similar solvent conditions. Cells were counted after 24 and 48 hours 
of treatment and the percentage of proliferation between this time span was calculated in 
comparison to controls (controls were considered as 100 % proliferating cells and all other 
conditions were set in relation to this). MCF-7 and were seeded in 24 well plates, allowed to 
attach for 24 hours when extracts were applied as described above and cells counted after 24, 
48, and 72 hours. Experiments were done in triplicate. Error bars indicate SEM, and asterisks 
significant proliferation inhibition compared to control (p<0.05). 
 
Plant material Solvent IC 50 
L. sativa Lyophilized Petroleum ether 17 mg/ml
L. sativa Lyophilized Dichlormethan 14 mg/ml
L. sativa Lyophilized Ethyl acetate 20 mg/ml
L. sativa Lyophilized Methanol n.r.
L. sativa Lyophilized Water 3.3 mg/ml
(n.r. = not reached) 
Table 9: IC 50 - values of L. sativa 
 
4.3.3. Inhibition of proliferation by the water extract of L. sativa is 
preceded by the down-regulation of cell cycle protagonists  
4 mg/ml water extract of L. sativa caused phosphorylation and therefore an 
activation of Chk 2 after 30 minutes and intensified after 8 hours which was 
paralleled by a decrease of Cyclin D1 after 8 hours (figure 28a). This correlated 
with cell cycle inhibition of the water extract. On the other hand, ethyl acetate 
extract had no effect on Chk 2. After an incubation of 24 hours a decrease of 
Cyclin D1 was observed.  
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a) 
 
 
b) 
 
Figure 28 legend: Analysis of cell cycle-related protein and phospho-protein expression  
HL-60 cells (1x106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for 24 
hours when cells were incubated with 4 mg/ml ethyl acetate and water extract of L. sativa for 
0.5, 2, 4, 8, and 24 hours. Then, isolated protein samples were subjected to electrophoretic 
separation and subsequent Western blot analysis using antibodies against:  
(a) phospho-Thr68-Chk2, Chk2, cyclin D1; (b) p21, phospho-Thr202/Tyr204-Erk, and Erk. Equal 
sample loading was controlled by Poinceau S staining and β-actin analysis. 
 
Both extract types of L. sativa induced p21. Water extract showed a stronger 
effect than ethyl acetate but decreased after 4 hours while that of ethyl acetate 
persisted. 
Erk showed late phosphorylation of MAP-Kinase with water extract. Ethyl 
acetate caused a phosphorylation of Erk after 8 hours with a following drop, 
simultaneously with that of Cyclin D1.  
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4.3.4. The ethyl acetate and the water extract of L. sativa induce apoptosis 
First of all figure 29 shows that the extracts rather induced apoptosis in HL-60 
while in MCF-7 slightly induced necrosis at the highest concentration (20 mg/ml) 
but this wasn’t significant. The highest apoptosis induction could be achieved 
with 20 mg/ml water extract in HL-60 cells triggering around 60 % apoptotic cell 
death. The ethyl acetate extract showed a high apoptotic effect too with a rate 
of 30 %. To provide a possible explanation for the pro-apoptotic effect of EA- 
and in particular of the H2O-extract, which could have based on a potential 
KNO3 concentration, or on substantional amounts of phenolic components, 
respective tests were untertaken (see the following chapters). A non significant 
effect showed the extracts in MCF-7 cells. Only the water and methanol extract 
produces a minor necrotic effect of around 10 %.  
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Figure 29 legend:  Induction of apoptosis and necrosis by L. sativa 
HL-60 cells were incubated for 48 hours and MCF-7 cells for 96 hours with increasing extract 
concentrations. Then, cells were double stained with Hoechst 33258 and propidium iodide and 
examined under the microscope with UV light connected to a DAPI filter. Nuclei with 
morphological changes which indicated apoptosis or necrosis (see “Methods”) were counted 
and percentages of vital, apoptotic and necrotic cells were calculated. Experiments were done 
in triplicate. Error bars indicate SEM, and asterisks significant apoptosis induction compared to 
control (p<0.05).  
 
74/97 
 
As shown in figure 30, only the ethyl acetate extract induced acetylation of α-
tubulin. This implicates that the ethyl acetate extract stabilizes microtubule and 
therefore might trigger mitotic arrest and apoptosis, which was in fact observed 
at a concentration of 4 mg/ml, whereas this concentration of water extract hat 
no apoptotic effect.  
 
 
Figure 30 legend: Western blot analysis of tubulin acetylation 
HL-60 cells (1x106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for 24 
hours when cells were incubated with 4 mg/ml methanol extract derived from ethyl acetate and 
water extract of L. sativa for 0.5, 2, 4, 8, and 24 hours. Then, isolated protein samples were 
subjected to electrophoretic separation and subsequent Western blot analysis using antibodies 
against: acetylated-α-tubulin, α-tubulin, and β-tubulin. Equal sample loading was controlled by 
Poinceau S staining and β-actin analysis.  
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4.3.5. Analysis of a potential KNO3 effect 
To investigate wether the observed effects were due to KNO3, a fertilizer of 
which residual amounts are frequently found in L. sativa, HL-60 cells were 
incubated with 4 µg/ml KNO3 (4µg KNO3/g plant weight is allowed by the 
legislation in the European Union) for 0.5, 2, 4, 8 and 24 hours. Figure 31 
shows that KNO3 had no effect, neither on Chk2 nor on p21, whereas Cyclin D1 
expression was reduced after 8 hours, though not completely inhibited. 
Therefore the majority of the observed effects were not induced by fertilizer 
remnants.  
 
  
Figure 31 legend: Analysis of cell cycle-related protein and phospho-protein expression  
HL-60 cells (1x106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for 24 
hours when cells were incubated with 4 µg/ml KNO3 for 0.5, 2, 4, 8, and 24 hours. Then, 
isolated protein samples were subjected to electrophoretic separation and subsequent Western 
blot analysis using antibodies against: phospho-Thr68-Chk2, Chk2, cyclin D1; p21. Equal 
sample loading was controlled by Poinceau S staining and β-actin analysis. 
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4.3.6. Total phenolic content of L. sativa ethylacetate- and water extract 
The calculated total phenolic content (expressed as gallic acid and equivalents; 
table 10), was 3.18 mg/100 g in the ethyl acetate extract and 42.25 mg/100 g in 
water extract of L. sativa. Heimler et al. found higher polyphenol contents (about 
one - two orders of magnitude) in lettuce varieties. This discrepancy may be 
linked to the different extraction conditions. The low value in the ethyl acetate 
extract is based on the fact that phenolic compounds are not soluble in this 
solvent. Most phenolics, tannins, etc. are soluble in methanol and therefore 
remain in the methanol extract. Thats why the total phenolic amount in the 
water extract was low too, because this extraction was subsequent to that with 
methanol. Therefore, the antiproliferative and antiapoptotic effect didn´d result 
from phenolics whether in ethyl acetate nor in water extract. 
 
L. sativa µg gallic acid equivalent 
(after extraction) 
g fresh plant  total phenolics 
(expressed as mg gallic 
acid/100g fresh plant) 
Ethyl Acetate 22.91 0.72 3.18 
Water 35.07 0.083 42.25 
Table 10: Total phenolics (Folin-Ciocalteu Method)  
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5. DISCUSSION 
 
To enable an initial and preliminary separation of plant components, the dried 
plant materials were serially/sequentially extracted with solvents of increasing 
polarity, which facilitated that different chemical substances from the plants 
were dissolved in the various extract types. Therefore, the five solvents 
exhibited distinct activities. In detail, the plant extracts were tested regarding 
their anti-leukaemic potentials such as the inhibition of proliferation and the 
induction of leukaemia cell death because these are hallmark for anti-neoplastic 
activities.  
 
5.1. S. podophyllum 
 
S. podophyllum can be found as a natural product against cancer and is 
recommended because of its anti-inflammatory-activity (Arvigo and Balick 
1998). The Mayan use the plant against rheumatism, arthritis and swellings. 
However, the performed COX-Inhibitor Screening Assay showed that COX-2 
isn´t believed to be the target enzyme of the analysed methanol extract, and 
therefore PGH2 is not the crucial metabolite. The anti-proliferative effects which 
are a hallmark for anti-tumor activity were only moderate in HL-60 cells upon S. 
podophyllum extract application. It can be speculated that the empirical anti-
tumor effects observed by traditional healers were not due to cell cycle-
inhibitory or pro-apoptotic properties (although we did not analyse the pro-
apoptotic potential of S. podophyllum, because both mechanisms mostly appear 
together), but due to anti-angiogenic or anti-invasive properties, which have not 
been monitored by the here applied methods.  
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5.2. P. odorata 
 
The anti-cancer effects of P. odorata, most and for all the pro-apoptotic 
properties were highly significant. The dichlormethane extract of P. odorata 
exhibited much higher activity. In the Mayan medicine decoctions of P. odorata 
are used to treat neuritis, rheumatic pain, and arthritis and early stage tumours. 
Patients are supposed to drink this decoction for several days in considerable 
quantities to treat cough and flu without side effects (Arvigo and Balick 1998). 
 
P. odorata dose dependently arrested the cell cycle in G2-M phase. The 
interference with three independent mitotic mechanisms may have stalled the 
cells in this phase:  
1) the de-phosphorylation of p44 and p42 mitogen activated protein (MAP) 
kinases (synonyms: Erk1 and Erk2), which function in a protein kinase 
cascade that plays a critical role in the regulation of cell growth and 
differentiation (Marshall 1995; Hunter 1995; Hill and Treismann 1995; 
Cowley et al. 1994), within 2 hours and therefore interruption of mitotic 
signaling. MAP kinases are activated by a wide variety of extracellular 
signals and transduce these mitotic signals through phosphorylation of 
threonine and tyrosin residues (Sturgill et al. 1983; Payn et al. 1991). 
2) the P. odorata dichloromethan extract suppressed Cyclin D1 within 8 
hours, which is required for the activation of Cdk4 and Cdk6 (Alao 2007; 
Lingfei et al. 1998), thereby affecting cell cycle progression. The D family 
of cyclins has been associated with a wide variety of proliferative 
diseases and cyclin D1 is classified as a proto-oncogene. Temporally the 
D cyclins appear in early G1, before the B cyclins, in the course of the 
cell cycle (Xiong et al. 1992a; Xiong et al. 1992b; Inaba et al. 1992).  
3) induction of checkpoint kinase 2 and consequently degradation of 
Cdc25A within 24 hours. Also Cdc25A is a proto-oncogene and 
coordinates the transit from G1 to S and also contributes to G2-M transit. 
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The cell cycle inhibitors p21 (which did not become upregulated; data not 
shown) and p27 (which became even downregulated) did not seem to play a 
role in this process. 
P. odorata dichloromethane extract dose dependently triggered apoptosis which 
was preceded by an activation of Caspase-3 and degradation of its target 
PARP1. The proapoptotic potential was extraordinarily high, as 25 µg/ml dried 
extract remnant (corresponding to ~1 mg/ml dried plant weight) induced ~ 50 % 
cell death. The activity which inhibited 50 % proliferation were calculated 0.7 
mg/ ml dried plant weight and it is very likely, that apoptosis had already a major 
contribution to this “anti-proliferative” activity. Both mechanisms were 
overlapping at the time points measured (and cannot be dissected by differently 
scheduled timing) and this allows the conclusion that the dichloromethane 
extract of P. odorata harbours an extraordinarily potent pro-apoptotic principle, 
which can be exploited for the development of a novel anti-cancer therapeutical 
approach. Pluchea species were shown to contain polyphenols, terpenoids and 
flavonoids (Alonso-Lopez et al. 1985; Wollenweber et al. 1985; Arriaga and 
Borges-del-Castillo 1985a; Arriaga and Borges-del-Castillo 1985b). When 
tested in HL-60- and other kinds of cancer cells, flavonoids and other 
(poly)phenolic compounds were shown to elicit apoptosis and inhibit the cell 
cycle. Frequently however, the proapoptotic concentrations had to be 
severalfold higher than those concentrations which inhibited proliferation (Bader 
et al. 2008; Madlener et al. 2007; Saiko et al. 2007; Horvath et al. 2006; Grusch 
et al. 2001; Rosenberger et al. 2000; Fritzer-Szekeres et al. 2000). This 
underscores the effectiveness of the P. odorata extract, which may be based on 
the synergistic activation of several pro-apoptotic principles. 
 
Tubulins play a prevalent role in the differentiation of microtubule structure and 
function. Fine tuned orchestration of tubulin polymerization/de-polymerization 
events are required to enable mitotic spindle arrangements and cytokinesis. 
Therefore, the severe affection of tubulin dynamics upon stabilization is 
incompatible with functional cell division (Piperno and Fuller 1985) and causes 
mitotic catastrophe. Taxol exerts its anticancer effect by stabilizing/polymerizing 
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microtubules, which in turn triggers apoptosis due to mitotic arrest (Geney et al. 
2005; Marcus et al. 2005). On the contrary, de-stabilization of tubulin such as by 
vincristine or colchicine, is cytotoxic (Marcus et al. 2005). Thus, tubulin-targeting 
drugs are validated anti-cancer therapeutics (Jordan and Wilson 2004). The 
polymerization of microtubules such as by taxol is associated with increased 
acetylation of α–tubulin, which is an established marker for microtubule stability 
(Piperno et al. 1987), because only polymerized but not non-polymerized 
microtubules become acetylated (Wilson and Forer 1997; Matsuyama et al. 
2002). Histone deacetylase 6 (HDAC6) is to date the only known enzyme 
specifically de-acetylating α–tubulin (Hubbert et el. 2006) and hence, it controls 
the dynamics and stability of microtubules by promoting their disassembly 
(Matsuyama et al. 2002) and inhibition of HDAC6 results in α–tubulin acetylation 
on lysine 40 (Piperno et el. 1987). Also the inhibition of farnesyl transferase 
increases α–tubulin acetylation (Marcus et al. 2005) probably due to affection of 
the activity of the farnesyl-carrying mitotic microtubule-associated proteins 
CENP-E (Crespo et al. 2002).  
Incubation with P. odorata dichloromethan extract rapidly (after 30 minutes) 
increased the acetylation of α-tubulin that still persisted after 24 hours of 
incubation. Therefore, this extract contained α-tubulin targeting activity, 
reminiscent of taxol, and arrested cells in G2-M causing mitotic catastrophe and 
cell death. The mechanism by which P. odorata extract interfered with 
microtubule dynamics will be addressed in future investigations. 
To rule out the possibility, that the dichloromethane extracts generally contain 
non-specific toxic components we compared a dichloromethane extract 
prepared from L. sativa var. capitata, the green “iceberg” salad. Only the 
highest concentration tested (20 mg/ml) inhibited HL-60 cell proliferation but did 
not induce apoptosis and the dichloromethane rhizome extract of S. 
podophyllum was even less active. At the 4 mg/ml concentration, at which also 
the P. odorata extract was investigated by FACS- and by western blot analyses, 
L. sativa dichloromethane extract neither inhibited Cdc25A or cyclin D1 
expression nor did caspase 3 become activated. Instead, it induced the 
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phosphorylation of Erk although we did not observe an acceleration of 
proliferation. 
New agents with prospective anti-cancer activity are usually tested in a panel of 
60 distinct cancer cell lines representing 9 distinct tumor entities (Weinstein 
1997). However, the vast majority of all agents, which exhibit activity in the 60 
cell line screen, are also active in MCF-7 breast cancer cells (Cragg 2000). 
Therefore, the dichloromethane extract of P. odorata was also tested in MCF-7 
breast cancer cells and found to inhibit cell proliferation by ~ 90 % at a 
concentration of 4 mg/ml.  
Upon testing whether P. odorata apolar dichloromethane-soluble constituents 
only target cancer cells we found that in the human immortalized anomalous 
breast epithelial cell line MCF-10A the antiproliferative effects were similar to 
those observed in MCF-7 cancer cells. This is most likely due to the fact that 
both cell lines duplicate similarly and also the vast majority of currently applied 
anti-cancer drugs combat cancer cells because they replicate faster than 
normal cells. Among polyphenols, flavonoids, and sesquiterpenes there are a 
plethora of bio-active compounds and studies more than 20 years ago analysed 
P. odorata regarding its constituents. It was shown that it contains flavonoids, 
triterpenes (Alonso-Lopez et al. 1985; Wollenweber et al. 1985), phytosterols 
(Dominguez and Zamudio 1972), and Plucheinol, a new eudesmane type 
sesquiterpen unique to P. odorata (Arriaga and Borges-del-Castillo  1985a; 
Arriaga and Borges-del-Castillo 1985b). A comparison between two P. odorata 
populations from Mexico and El Salvador showed that the Mexican population 
contained a greater number of triterpenes and flavonoids, whereas the 
population from El Salvador contained a greater number of sesquiterpenes 
(Wollenweber et al. 1985; Arriaga-Giner et al. 1983). Whether the different P. 
odorata populations also exhibit different anti-cancer activity needs to be 
established and could elucidate which type(s) of the plant constituents may be 
responsible for the here described effects. 
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5.2. L. sativa 
 
Unexpectedly, L. sativa water extract showed a distinct antiproliferativ effect in 
HL-60 cells, so we decided to perform further analysis to clarify it´s 
effectiveness. In both cell types, HL-60 and MCF-7, a growth inhibition of 50 % 
at a concentration of 4 mg/ml could be achieved with the water extract. All the 
other extract types showed only a weak inhibition. In the cell death assay water 
and ethyl acetate extract triggered apoptosis. That´s why this two extract types 
were used for western blot analysis and total phenolics determination. 
 
The water extract was tested in a similar way as the P. odorata extracts shown 
before. Chk2 was activated after 30 minutes which was paralled by a decrease 
of Cyclin D1 after 8 hours and therefore Cdk 4 and Cdk 6 were inactivated (Alao 
2007; Lingfrei et al. 1998) resulting in an inhibition of the cell cycle progression. 
Furthermore, L. sativa upregulated p21, a specific inhibitor of Cdks, after 4 
hours. This 21 kDa Cdk-interacting protein, p21, has been identified in cyclin A, 
cyclin D1 cyclin E and Cdk2 immunoprecipitates. The upregultation of p21 was 
independent of p53, which is the major regulator of p21, because HL-60 cells 
are p53 negative (Biroceccio et al. 1999). Additionally, the water extract induced 
long lasting phosphorylation of MAP-Kinase and therefore conflicting mitotic 
signaling. The ethyl acetate extract showed only a slight decrease of Cyclin D1 
after an incubation of 24 hours and had no effect on Chk2. After 8 hours Erk 
was phosphorylated with a following drop, simultaneously with that of Cyclin D1.  
 
In HL-60 cells L. sativa ethyl acetate and water extract triggered apoptosis at a 
concentration of 20 mg/ml. The proapototic potential, particularly of ethyl 
acetate, was relatively high. Even a concentration of 4 mg/ml causes apoptosis 
in 20 % of the cells. This correlates with previous investigations that Lactuca 
variants induce apoptosis in HL-60 cells (Chen et al. 2007). By contrast both 
extract types had no effect in MCF-7 cells. Only the water extract slightly 
induced necrosis at the highest concentration (20 mg/ml).  
83/97 
 
At a concentration of 4 mg/ml the ethyl acetate extract induced acetylation of α-
tubulin after two hours and persisted after 24 hours of incubation. Therefore the 
ethyl acetate extract might trigger mitotic arrest and apoptosis, while the water 
did not show an influence. 
 
To investigate wether the observed effects were due to KNO3, a fertilizer of 
which residual amounts are frequently found in L. sativa, HL-60 cells were 
treated with 4 µg/ml KNO3 (4 µg KNO3/g fresh plant weight is allowed by the 
legislation in the European Union). The amount of nitrate markedly varies 
depending on the varety of vegetables, genetic factors, agricultural practices, 
climatic conditions, degree of maturity, and light. (Tosun and Ustun 2004). The 
conclusion was that KNO3 had no effect on Chk2 or on p21. Only Cyclin D1 
expression was slightly reduced after 8 hours. Therefore the antiproliferative 
and apoptotic effect of L. sativa were not induced by fertilizer remnants but by 
other mechanism(s). 
 
A variety of polyphenolic compounds were investigated in different lettuce 
genotypes, for example quercetin, kaempferol, luteolin, apigenin, and crysoeriol 
derivates (Heimler et al. 2007; Hohl et al. 2001). The total phenolic content in L. 
sativa expressed as gallic acid equivaltents was 3.18 mg/100 g fresh weight in 
ethyl acetate extract and 42.25 mg/ 100 g fresh weight in water extract. This is 
10-fold less than the total content of phenolic compounts found by Heimler et al. 
2007. This discrepancy may be based on the fact that gallic acid is insoluble in 
ethyl acetate but soluble in methanol. That´s why only small amounts of gallic 
acid remained in the extracts investigated (ethylacetate and water).  
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6. CONCLUSION 
 
Leukaemias are characterized by an abnormal proliferation of blood cells, 
mostly leukocytes, but these diseases often escape after successful treatment. 
Therefore, we tested novel therapeutic concepts in the human promyeloic 
leukaemia cell line HL-60 and chose a highly interdisciplinary approach that 
involved the long lasting empirical knowledge of the Maya, a more than 
thousand year old civilization with a highly developed plant-medicinal tradition. 
Maya medicine was unaware of leukaemia or cancer and therefore no remedies 
against these diseases were discovered. Our concept of plant selection is their 
traditional use against severe inflammations, because there are a variety of 
similar signalling pathways which are commonly up-regulated both in 
inflammatory conditions and in cancer. Here we compared the in vitro 
anticancer effects of extracts of two anti-inflammatory plants, S. podophyllum 
and P. odorata. As a negative control L. sativa was tested with the same 
methods like the other two plants.  
 
The anti-proliferative effect of S. podophyllum was only moderate in HL-60 cells 
and the COX-Inhibitor Screening Assay showed no result. So we skipped 
further analysis with this plant. 
 
On the other side, P. odorata extracts showed distinct antiproliferative effects. 
Particularly the proapoptotic properties were powerful. The dichloromethane 
extract of P. odorata contains apolar constituents, because the most effective 
was the dichlormethan extract, which inhibited inflammatory responses and 
exhibited anti-cancer activity, tested in HL-60, and MCF-7. P. odorata dose 
dependly arrested the cell cycle in G2-M phase based on the activation of 
checkpointkinase 2, and downregulation of Cdc25A and Cyclin D1 as well as 
inactivation of Erk1/2. The strong pro-apoptotic potential, through activation of 
Caspase 3 followed by PARP signature type cleavage, warrants further 
bioassay-guided fractionation to discover and investigate the active principle(s). 
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The hypothesis, that anti-inflammatory remedies might also be useful as 
anticancer agents in vitro was not valid for S. podophyllum but could be verified 
for P. odorata. This is a 50:50 situation and has therefore a much higher 
success rate regarding the identification of novel anti-cancer remedies 
compaired to the rate observed when testing randomly collected (healing) 
plants. 
 
L. sativa water extract showed an antiproliferative effect in HL-60 and MCF-7 
cells through the activation of Chk2 and at the same time by a downregulation 
of Cyclin D, an upregulation of p21 and a phosphorylation of Erk1/2. Thereby 
the mitotic signaling was disrupted. Furthermore the water and the ethyl acetate 
extract triggered apoptosis in HL-60 cells, while the extracts hat no effect in 
MCF-7 cells. These surprising finding opens up the possibility for further 
research to detect the exact source, which is responsible for the distinct anti-
cancerogenic effect of L. sativa.  
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7. SUMMARY 
 
The aim of this diploma thesis was to investigate the anti-neoplastic potential of 
two healing plants,who were already used by the Maya of the Guatemala/Belize 
area against severe inflammatory conditions such as neuritis, rheumatism, 
arthritis, coughs, bruises and tumours.  
S. podophyllum and Pluchea odorata were collected, dried, and extracted with 
five solvents of increasing polarity. To rule out the possibility, that the different 
solvent types contain non-specific toxic components we compared different 
extracts prepared from L. sativa var. capitata, the green “iceberg” salad. The 
inhibition of proliferation and the induction of cell death were investigated in HL-
60 and MCF-7 cells, because these are endpoints to measure the efficiency of 
anti-cancer drugs. Western blot and FACS analyses aimed to obtain data on the 
underlying mechanisms. 
While extracts of S. podophyllum showed only moderate anti-cancer activity and 
were therefore not further investigated, particularly the dichloromethane extract 
of P. odorata inhibited the cell cycle in G2-M which correlated with the activation 
of checkpoint kinase 2, and the down-regulation of Cdc25A and cyclin D1 as 
well as the inactivation of Erk1/2. This extract was an extraordinarily strong 
inducer of HL-60 and MCF-7 cell death activating caspase 3 followed by PARP 
signature type cleavage. The initiating death trigger was likely the stabilization 
of microtubules monitored by the rapid acetylation of α-tubulin, which was even 
more pronounced than that triggered by taxol.  
L. sativa water extract showed a distinct antiproliferative effect in HL-60 and 
MCF-7 cells. It works in a similar way than P. odorata. Chk2 was activated 
which was paralelled by Cyclin D downregulation and p21 upregulation. 
Additionally, Erk1/2 was phosphorylated and therefore mitotic signaling was in 
conflict with p21 downregulation. Furthermore the water- and the ethyl acetates 
extract triggered apoptosis in HL-60 cells, while the extracts had no effect in 
MCF-7 cells.  
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8. ZUSAMMENFASSUNG 
 
Das Ziel dieser Diplomarbeit war es das Potential von zwei Heilpflanzen zu 
untersuchen, die von den Mayas aus El Petén/Guatemala gegen 
Entzündungen, wie zum Beispiel gegen Neuritis, Rheuma, Arthritis, 
Erkältungen, Blutergüsse und Tumore, genutzt werden.  
S. podophyllum und P. odorata wurden gesammelt, getrocknet und 
anschließend mit fünf Lösungsmitteln mit ansteigender Polarität extrahiert. Um 
die Möglichkeit auszuschließen, dass die unterschiedlich polaren Lösungsmittel 
Komponenten aus Pflanzen enthalten, die speziesübergreifend in 
verschiedensten Pflanzen enthalten sind, und in erhöhter Konzentration 
generell zell-toxisch wirken, verglichen wir sie mit verschiedenen Extrakte von 
L. sativa var. capitata, dem grünen „Eisberg“ Salat. Die Proliferationshemmung 
und die Induktion des Zelltodes wurden in HL-60 und MCF-7 Zellen ermittelt. 
Mit Hilfe von Wester blot und FACS Analysen wurde versucht die 
grundliegenden Mechanismen zu ermitteln.  
Während die Extrakte von S. podophyllum nur moderate anti-kanzerogene 
Aktivitäten zeigten und daher nicht weiter analysiert wurden, inhibierte vor allem 
das Dichlormethanextrakt von P. odorata den Zellzyklus in der G2-M Phase. 
Gleichzeitig wurde der Checkpoint Kinase 2, Cdc25A und Cyclin D1 
herunterreguliert und Erk ½ inaktiviert. Dieses Extrakt induzierte 
außergewöhnlich stark den Zelltod in HL-60 und MCF-7 Zellen durch eine 
Caspase 3 Aktivierung mit darauffolgender PARP signature type cleavage. Der 
Auslöser des Zelltodes war wahrscheinlich die Stabilisierung der Mikrotubulie.  
Das Wasser Extrakt von L. sativa zeigte einen distinktiven antiproliferativen 
Effekt in HL-60 und MCF-7 Zellen. Der Wirkungsmechanismus ist dem von P. 
odorata ähnlich: Chk2 wird aktiviert. Parallel dazu finden eine Herabregulation 
von Cyclin D und eine Aufregulation von p21 statt. Zusätzlich wird Erk1/2 
phosphoryliert was gegensätzlich zur p21 Herabregulation steht. Außerdem 
induziert das Wasser- und das Ethylacetatextrakt apoptotischen Zelltod in HL-
60 Zellen während sie keinen apoptotischen Einfluss auf MCF-7 Zellen hatten.  
 
88/97 
 
9. REFERENCES 
 
Alao JP: The regulation of cyclin D1 degradation: roles in cancer development 
and the potential for therapeutic invention. Molecular Cancer: 6-24, 2007. 
 
Alonso-Lopez M, Arriaga-Giner FJ, Borges-del-Castillo J and Vasquez-Bueno 
P: N-alkanes and triterpenoids from some Salvadorian compositae. Fitoterapia 
56(2): 123-125, 1985. 
 
Arriaga FJ and Borges-del-Castillo J: A new eudesmane derivative from 
Pluchea odorata. Planta Medica 51(3): 290, 1985a. 
 
Arriaga FJ and Borges-del-Castillo J: Carbon-13 NMR spectra of Plucheinol and 
its ester derivatives. Magn. Res. Chem. 23(6): 478-488, 1985b. 
 
Arriaga-Giner FJ, Borges-del-Castillo J, Manresa-Ferrero MT, Vasquez-Bueno 
P, Rodriguez-Luis F and Valdes-Iraheta S: Eudesmane derivatives from 
Pluchea odorata. Phytochemistry 22(8): 1767-1769, 1983. 
 
Arvigo R and Balick M: Rainforest Remedies, Lotus Press, Twin Lakes WI, 
1998. 
 
Bader Y, Madlener S, Strasser S, Maier S, Saiko P, Stark N, Popescu R, Huber 
D, Gollinger M, Erker T, Handler N, Szakmary A, Jäger W, Kopp B, Tentes I, 
Fritzer-Szekeres M, Krupitza G and Szekeres T: Stilbene analogues affect cell 
cycle progression and apoptosis independently of each other in an MCF-7 array 
of clones with distinct genetic and chemoresistant backgrounds. Oncol Rep. 
19(3): 801-10, 2008. 
 
Biroccio A, Del Bufalo D, Ricca A., D´Angelo C, D´Orazi G, Sacchi A, Soddu S 
and Zupi G: Increase of BCNU sensitivy by wt-p53 gene therapy in glioblastoma 
lines depends on the administration schedule. Gene Therapy 6: 1064-1072, 
1999. 
 
Branzei D and Foiani M: Regulation of DNA repair throughout the cell cycle. 
Nature Reviews – Molecular cell biology Volume 9: 297-308, 2008. 
 
Chen YH, Chen HY, Hsu CL and Yen GC: Induction of Apoptosis by Lactuca 
indica L. in Human Leukemia Cell Line and its active Components. J. Argric. 
Food Chem. 55: 1743-1749, 2007. 
 
Coussens LM and Werb Z: Inflammation and Cancer. Nature 420(6917): 860-7, 
2002. 
 
Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase 
kinase is necessary and sufficient for PC12 differentiation and for 
transformation of NIH 3T3 cells. Cell 77: 841-852, 1994. 
89/97 
 
Cragg GM and Newman DJ: Antineoplastic agents from natural sources: 
achievements and future directions. Expert Opin Investig Drugs 9: 2783-2797, 
2000. 
 
Cragg GM, Newman DJ and Yang SS: Natural product extracts of plant and 
marine origin having antileukemia potential. The NCI experience (Review). J 
Nat Prod. 69(3): 488-98, 2006. 
 
Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD and Sebti SM: The 
farnesyl-transferase inhibitor, FTI-2153, inhibits bipolar spindle formation during 
mitosis independently of transformation and Ras and p53 mutation status. Cell 
Death Differ. 9(7): 702-9, 2002. 
 
Newman DJ and Cragg GM: Natural Products as Sources of New Drugs over 
the last 25 years. Journal of Natural Products. Vol. 70, No. 3: 461-477, 2006. 
 
Denecker G, Vercammen D, Declercq W and Vandenabeele P: Apoptotic and 
necrotic cell death induced by death domain receptors. CMLS Cell. Mol. Life 
Sci. Vol. 58: 356-370, 2001. 
 
Dewanto V, Wu X, Adom KK and Liu RH: Thermal processing enhances the 
nutritional value of tomatoes by increasing total antioxidant activity. J. Agric. 
Food Chem. 50: 3010-3014, 2002. 
 
Dipankar R and Hiroaki K: Cdc25a Phosphatase: a Rate-limiting Oncogene that 
determines genomic stability. Cancer Res. 68 (5): 1251-1253, 2008. 
 
Dmitri V, Krysko T, Berghe V, D´Herde K and Vandenabeele P: Apoptosis and 
necrosis: Detection, discrimination and phagocytosis. Methods 44: 205-221, 
2007. 
 
Dolezal K, Popa I, Krystof V, Spíchal L, Fojtíková M, Holub J, Lenobel R, 
Schmülling T and Strnad M: Preparation and biological activity of 6-
benzylaminopurine derivatives in plants and human cancer cells. Bioorg Med 
Chem. 14(3): 875-84, 2006. 
 
Dominguez XA and Zamudio A: β-amyrin acetate and campestereol from 
Pluchea odorata. Phytochemistry 11(3): 1179, 1972. 
 
Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human 
apoptotic protein with homology to Caenorhabditis elegans cell death protein 
Ced-3 and mammalian interleukin-1 beta- converting enzyme. J. Biol. Chem. 
269: 30761-30764, 1994. 
 
Fritzer-Szekeres M, Grusch M, Luxbacher C, Horvath S, Krupitza G, Elford HL 
and Szekeres T: Trimidox, an inhibitor of ribonucleotide reductase, induces 
apoptosis and activates caspases in HL-60 promyelocytic leukemia cells. Exp 
Hematol. 28(8): 924-30, 2000. 
90/97 
 
Geney R, Sun L, Pera P, Bernacki RJ, Xia S, Horwitz SB, Simmerling CL and 
Ojima I: Use of the tubulin bound paclitaxel conformation for structure-based 
rational drug design. Chem Biol. 12(3): 339-48, 2005. 
 
Groves FD, Linet MS and Devesa SS: Epidemiology of human leukemia; Curr 
Opin Hematol 1(4): 321-6, 1994. 
 
Grusch M, Fritzer-Szekeres M, Fuhrmann G, Rosenberger G, Luxbacher C, 
Elford HL, Smid K, Peters GJ, Szekeres T and Krupitza G: Activation of 
caspases and induction of apoptosis by novel ribonucleotide reductase 
inhibitors amidox and didox. Exp Hematol. 29(5): 623-32, 2001. 
 
Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, 
Fuhrmann G, Kassie F, Steinkellner H, Smid K, Peters GJ, Jayaram HN, Klepal 
W, Szekeres T, Knasmuller S and Krupitza G: Maintenance of ATP favours 
apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ. 
9(2): 169-78, 2002. 
 
Hanahan D and Weinberg RA: The Hallmarks of Cancer. Cell. Vol. 100: 57-70, 
2000. 
 
Heimler D, Isolani L, Vignolini P, Tombellinin S and Romani A: Polyphenol 
Content and Antioxidative Activity in Some Species of Freshly Consumed 
Salads. J. Agric. Food Chem. 55: 1724-1729, 2007. 
 
Hill CS and Treisman R: Transcriptional regulation by extracellular signals: 
mechanisms and specificity. Cell 80: 199-211, 1995. 
 
Hohl U., Neubert B., Pforte H., Schonhof I., Böhm H., (2001) Flavonoid 
concentrations in the inner leaves of head lettuce genotypes. Eur Food Res 
Technol. 213:205-211 
 
Horvath Z, Murias M, Saiko P, Erker T, Handler N, Madlener S, Jaeger W, 
Grusch M, Fritzer-Szekeres M, Krupitza G and Szekeres T: Cytotoxic and 
biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol 
analog in HL-60 human promyelocytic leukemia cells. Exp Hematol. 34(10): 
1377-84, 2006. 
 
http://www.accessexcellence.org/RC/VL/GG/images/MITOSIS2.gif (25.05.08) 
 
UK Breast Cancer incidence statistics 
http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/ (25.05.08) 
 
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, 
Wang XF and Yao TP: HDAC6 is a microtubule-associated deacetylase. 
Nature. 23;417(6887): 455-8, 2002. 
 
91/97 
 
Huettenbrenner S, Maier S, Leisser C, Polgar D, Strasser S, Grusch M and 
Krupitza G:  The evolution of cell death programs as prerequisites of 
multicellularity (Review). Mutat Res. 543(3): 235-49, 2003. 
 
Hunter T: Protein kinases and phosphatases: the yin and yang of protein 
phosphorylation and signaling. Cell 80: 225-236, 1995. 
 
Inaba T, Matsushime J, Beach D and Ward DC: Genomic organization, 
chromosomal localization, and independent expression of human cyclin D 
genes. Genomics 13: 565-574, 1992. 
 
Lingfei K, Pingzhang Y, Zhengguo L, Jianhua G and Yaowu Z: A study on p16, 
pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. Cancer Lett. 
130(1-2): 93-101, 1998. 
 
Madlener S, Illmer C, Horvath Z, Saiko P, Losert A, Herbacek I, Grusch M, 
Elford HL, Krupitza G, Bernhaus A, Fritzer-Szekeres M and Szekeres T: Gallic 
acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 
promyelocytic leukemia cells. Cancer Lett. 245(1-2): 156-62, 2007. 
 
Marchart E, Krenn L and Kopp B: Quantification of the flavonoid glycosides in 
Passiflora incarnata by capillary electrophoresis. Planta Med. 69(5):452-6, 
2003. 
 
Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao 
TP, Khuri FR and Giannakakou P: The synergistic combination of the farnesyl 
transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and 
requires a functional tubulin deacetylase. Cancer Res. 65(9): 3883-93, 2005. 
 
Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus 
sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 
1995. 
 
Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny 
D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S and Yoshida M: 
In vivo destabilization of dynamic microtubules by HDAC6-mediated 
deacetylation. EMBO J. 21(24): 6820-31, 2002. 
 
Meeran S.M., Kumar Katiyar S.K., (2008) Cell cycle control as a basis for 
cancer chemoprevention through dietary agents. Frontiers in Bioscience 13. 
2191-2202, January 1 
 
Payne DM, Rossomando AJ, Martino P. Erickson AK, Her JH, Shabanowitz J, 
Hunt DF, Weber MJ and Sturgill TW: Identification of the regulatory 
phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). 
EMBO J. 10: 885-892, 1991. 
 
92/97 
 
Pieper AA, Verma A, Zhang J and Snyder SH: Poly (ADP ribose) polymerase, 
nitric oxide and cell death. Trends Pharmacol Sci. 20 (4):171-81, 1999. 
 
Pietenpol JA and Stewart ZA: Cell cycle checkpoint signaling: Cell cycle arrest 
versus apoptosis. Toxicology 181-182: 475-481, 2002. 
 
Piperno G and Fuller M: Monoclonal antibodies specific for an acetylated form 
of alpha-tubulin recognize the antigen in cilia and flagella from a variety of 
organisms. J. Cell Biol. 101: 2085-94, 1985. 
 
Piperno G, LeDizet M and Chang XJ: Microtubules containing acetylated alpha-
tubulin in mammalian cells in culture. J Cell Biol. 104(2): 289-302, 1987. 
 
Rakoff-Nahoum S: Why cancer and inflammation? (Review). Yale J Biol Med. 
79(3-4): 123-30, 2006. 
 
Ribeiro LR, Mantovani MS, Ribeiro DA and Salvadori DM: Brazilian natural 
dietary components (annatto, propolis and mushrooms) protecting against 
mutation and cancer (Review). Hum Exp Toxicol. 25(5): 267-72, 2006.  
 
Rosenberger G, Fuhrmann G, Grusch M, Fassl S, Elford HL, Smid K, Peters 
GJ, Szekeres T and Krupitza G: The ribonucleotide reductase inhibitor trimidox 
induces c-myc and apoptosis of human ovarian carcinoma cells. Life Sci. 
67(26): 3131-42, 2000. 
 
Saiko P, Ozsvar-Kozma M, Bernhaus A, Jaschke M, Graser G, Lackner A, 
Grusch M, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jaeger W, 
Fritzer-Szekeres M and Szekeres T:  N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-
3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide 
reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor 
activity with arabinofuranosylcytosine. Int J Oncol. 31(5): 1261-6, 2007. 
 
Sica A, Allavena P and Mantovani A: Cancer related inflammation: The 
macrophage connection. Cancer Lett. 267(2): 204-15, 2008. 
 
Singleton VL, Orthofer R and Lamuela-Ravetos R: Analysis of total phenols and 
other oxidation substrates and antioxidans by means of the Folin-Cioclateu 
reagent. Methods Enzyml. 299: 152-178, 1999. 
 
Sturgill TW, Erikson LBRE and Maller JL: Insulin-stimulated MAP-2 kinase 
phosphorylates and activates ribosomal protein S6 kinase II. Nature 334: 715-
718, 1988. 
 
Sugimura T: Food and Cancer; Toxicology 181-182:17-21, 2002. 
 
Tosun I and Ustun NS: Nitrate content of lettuce grown in the Greenhouse. Bull. 
Environ. Contam. Toxicol. 72:109-113, 2004. 
 
93/97 
 
Van der Heuvel S: Cell-cycle regulation. WormBook Sep21: 1-16, 2005. 
 
Van Kempen LC, De Visser KE and Coussens LM: Inflammation, proteases and 
cancer. European Journal of Cancer 42 (6): 728-34, 2006. 
 
Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, 
Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, 
Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan 
VN, Johnson GS, Wittes RE and Paull KD: An information-intensive approach to 
the molecular pharmacology of cancer. Science 275: 343-349, 1997. 
 
Li W, Lam MS, Birkeland A, Riffel A, Montana L, Sullivan ME, Joseph M: Cell-
based assays for profiling activity and safety properties of cancer drugs. Journal 
of Pharmacological and Toxicological Methods 54: 313-319, 2006. 
 
Wilson PJ and Forer A: Effects of nanomolar taxol on crane-fly spermatocyte 
spindles indicate that acetylation of kinetochore microtubules can be used as a 
marker of poleward tubulin flux. Cell Motil Cytoskeleton 37(1): 20-32, 1997. 
 
Wollenweber E, Mann K, Arriaga FJ and Yatskievych G: Flavonoids and 
terpenoids from the leaf resin of Pluchea odorata. J. Biosciences 40C(5-6): 321-
324, 1985. 
 
World Cancer Research Fund / American Institute for Cancer Research. Food, 
Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. 
Washington DC: AICR, 2007.  
 
Xiong Y, Menninger J, Beach D and Ward DC: Molecular cloning and 
chromosomal mapping of CCND genes encoding human D-type cyclins. 
Genomics 13: 575-584, 1992b. 
 
Xiong Y, Zhang H and Beach D: D type cyclins associate with multiple protein 
kinases and the DNA replication and repair factor PCNA. Cell 71: 504-514, 
1992a. 
 
Yang X, Davies SM, Xiang Y, Robinson LL and Ross JA: Trends in Leukemia 
Incidence and Survival in the United States (1973-1998). CANCER Volume 
97/Number 9: 2229-2235, 2003. 
94/97 
 
10. DANKSAGUNG 
 
Ich bedanke mich bei meinem Betreuer Ao. Univ. Prof. Dr. Georg Krupitza für 
das Überlassen des Diplomarbeitsthemas, die ausgezeichnete Betreuung, 
seine Beratung in wissenschaftlichen und privaten Angelegenheiten und seine 
sehr hilfreiche Unterstützung bei Problemlösungen und spezifischen 
Fragestellungen. Ebenfalls bedanken möchte ich mich bei Ao. Univ. Prof. Dr. 
Karl-Heinz Wagner für die Betreuung und Unterstützung während meiner 
Diplomarbeit. 
 
Univ. Prof. Mag. Dr. Brigitte Kopp und den Mitarbeitern des Departments für 
Pharmakognosie danke ich sehr für die kompetente Betreuung während der 
Extraktion des Pflanzenmaterials. Besonders bedanken möchte ich bei Univ.-
Prof. Dr. Liselotte Krenn für die Durchführung der „Total phenolics 
determination“. 
 
Meinen Dank gilt weiters meinen Kolleginnen Mag. Sibylle Madlener, Mag. 
Nicole Stark, Mag. Thanh-Phuong Vo Nha und Mag. Ruxandra Popescu  für die 
sehr gute Zusammenarbeit in unserer Arbeitsgruppe und für die persönliche 
Unterstützung während der Erstellung der wissenschaftlichen Arbeit.  
 
Ganz besonders bedanken möchte ich mich bei meinen Eltern Gabriela Bohle-
Faast und Herbert Gridling die mir das Studium durch ihre großzügige 
finanzielle Unterstützung ermöglichten und mich meines gesamten Studiums 
immer hervorragend unterstützt haben. 
 
Schließlich möchte ich mich noch bei meinem Freund Clemens und all meinen 
Freunden für die tolle private Atmosphäre während meines Studiums bedanken. 
 
95/97 
 
11. LEBENSLAUF 
 
Name:   Manuela Gridling 
 
Geburtsdatum:  17. Februar 1981 
 
Geburtsort:   Dornbirn 
 
Schulbildung: 
 
 1987 – 1991 Volksschule Dorf / Lauterach 
 
 1991 – 1996 Bundesgymnasium Blumenstraße / Bregenz 
 
 1996 – 1999 Handelsschule Bregenz 
 
 2000 – 2003 Matura an der Handelsakademie Bregenz 
 (Aufbaulehrgang) 
 
Berufserfahrung: 
 
08/1999 – 08/2000Angestellte 
   Landesregierung Vorarlberg 
 
 Praktikas - ALMA Käsefabrikation & Export    
  reg.Gen.m.b.H./Bereich Qualitätskontrolle  
- Landesregierung Vorarlberg-Umweltinstitut/Bereich 
  Trink- und Badewässerkontrolle 
- Institut für Klinische Pathologie/Bereich   
  Tumorbiologie 
- Hermann Pfanner Getränke Ges.m.b.H. 
  Bereich Qualitätskontrolle 
 
 div. Ferienjobs ALMA Käsefabrikation & Export reg.Gen.m.b.H./Bereich 
Produktion 
  POST AG – administrative Tätigkeiten 
 
Studium: 
 
 ab Okt. 2003 Studium der Ernährungswissenschaften an der 
Universität Wien 
 
 Jun. 2007 – Jun. 2008 Diplomarbeit am Institut für Klinische Pathologie, 
  Universität Wien,  
  Währinger Gürtel 18-20, 1090 Wien 
  Betreuer: Ao. Univ. Prof. Dr. Georg Krupitza 
Thema: „Analysis of ethno-medical plants of the Maya of 
Central America for the development of new lead 
compounds against cancer” 
96/97 
 
12. PAPERS in preparation 
 
In vitro anticancer activity of two ethno-pharmacological healing plants 
from Guatemala Pluchea odorata and Phlebodium decumanum 
Gridling M., Stark N., Madlener S., Lackner A., Popescu R., Prinz S., Benedek 
B., Diaz R., Foster M., Thanh-Phuong Vo N., Huber D., Gollinger M., Saiko P. , 
Mosgoeller W., de Martin R., Eytner R., Wagner K.H., Grusch M., Fritzer-
Szekeres M., Szekeres T., Kopp B., Frisch R., Krupitza G. 
 
Health beneficial in vitro effects of Lactuca sativa. 
Gridling M., Popescu R., Kopp B., Wagner K.H., Krenn L., Krupitza G. 
 
In vitro anticancer activity of two ethno-pharmacological healing plants 
from Guatemala Anthurium schlechtendalii and Syngonium podophyllum 
Stark N, Gridling M, Madlener S, Herbacek I., Lackner A., Popescu R, Prinz S., 
Benedek B., Diaz R, Foster M., Thanh-Phuong Vo N., Huber D., Gollinger M., 
Saiko P., Mosgöller W., deMatin R., Eiter R., Grusch., Szekeres T, Fritzer-
Szekeres M, Frisch M., Krupitza G. 
 
In vitro anticancer activity of the ethnopharmacological healing plant 
Hypericum adenotrichum endemic to west Turkey 
Özmen A., Gridling M., Madlener S., Thanh-Phuong Vo N., Stark N., Saiko P., 
Fritzer-Szekeres M., Szekeres T., Askin-Celik T., Krupitza G. 
 
In vitro anticancer activity of Scutellaria orientalis ssp. carica endemic to 
western Turkey 
Özmen A., Madlener S., Gridling M., Stark N., Saiko P., Michel B., Fritzer-
Szekeres M., Szekeres T., Askin-Celik T., Krupitza G. 
 
The role of piceatannol on primary transcription factor dependent steroid 
receptor function, the target gene expression of the transcription factors 
estrogen receptor and progesterone receptor 
Thanh-Phuong Vo N., Madlener S., Gridling M., Horvath S., Probst P., Szekeres 
T., Fritzer-Szekeres M., Jäger W., Krupitza G. 
 
Multifactorial anti-cancer effects of di-galloyl resveratrol encompass 
apoptosis, cell cycle arrest, and inhibition of lymphendothelial gap 
formation in vitro 
Madlener S, Saiko P, Stark N, Popescu R, Gridling M, Phuong Tan N., 
Herbacek I, Davidovits A, Venkateswarly Somepalii, Geleff S, Grusch M, 
Trimurtulu G, Fritzer-Szekeres M, SzekeresT, Krupitza G. 
 
97/97 
 
Multifactorial anti-cancer effects of di-galloyl resveratrol encompass 
apoptosis, cell cycle arrest, and inhibition of lymphendothelial gap 
formation in vitro 
Madlener S., Saiko P., Stark N., Popescu R., Gridling M., Thanh-Phuong Vo N., 
Herbacek I., Davidovits A., Venkateswarlu S., Geleff S., Grusch M., Kerjaschki 
D., Trimurtulu G., Fritzer-Szekeres M., Szekeres T., KrupitzaG., in prepartion 
 
13. POSTERS 
 
"In vitro anti-cancer activity of extracts derived from traditional healing 
plants" 
Popescu R., Madlener S., Stark N., Gridling M., Davidovits A., Diaz R., Tut F., 
Herbacek I., Konkímalla V.B., Somepalii V., Saiko P., Horvath Z., Geleff S., 
Frisch R., Grusch M., Mosgöller W., Szekeres T., Efferth T., Trimurtulu G., 
Fritzer-Szekeres M., Kopp B., Krupitza G.  
6^th  International Symposion on Ethnobotany Disciplines, Lima, Peru, 
September 2007 
 
"Multifactorial anti-cancer effects of di-galloyl resveratrol encompass 
apoptosis, cell cycle arrest, and inhibitionof lymphendothelial gap 
formation in vitro" 
Madlener S., Saiko P., Stark N., Popescu R., Gridling M., Thanh-Phuong Vo N., 
Herbacek I., Davidovits A., Venkateswarlu S., Geleff S., Grusch M., Trimurtulu 
G, Fritzer-Szekeres M., Szekeres T., Krupitza G  
Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Germany, May 
2008 
 
“In vitro anti-cancer activity of extracts and isolated compounds derived 
from traditional healing plants of the Mediterranean and Central America" 
Madlener S, Gridling M, Stark N, Popescu R, Konkimalla VB, Efferth T, Diaz R, 
Tut FM, Frisch R, Trimurtulu G, Lackner A, Herbacek I, Losert A,^ de Martin R, 
Eytner R, Vo NTP,^ Horvath Z, Saiko P, Fritzer-Szekeres M, Grusch M, Kopp B, 
Szekeres T, Krupitza G  
13^th World Congress on Advances in Oncology, 11^th International 
Symposium on Molecular Medicine, Chersonissos, Crete, October 2008 
 
